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Resumo 
 
 
Cancro da próstata, marcadores tumorais, lactato desidrogenase, 
antigénio prostático específico, sistemas aquosos bifásicos, concentração, 
purificação, líquidos iónicos 
 
 
O cancro da próstata representa nos dias de hoje a terceira causa de morte 
mais comum entre os homens, sendo que, atualmente, não existe nenhum 
tratamento eficaz quando o tumor é diagnosticado já num estado 
avançado. Tendo em conta as elevadas taxas de mortalidade associadas 
ao cancro, a identificação e quantificação de biomarcadores tumorais em 
fluidos e tecidos humanos têm sido alvo de uma investigação intensa no 
sentido de efetuar diagnósticos mais fiáveis e evitar tratamentos 
invasivos excessivos. Alguns biomarcadores tumorais, como o antigénio 
prostático específico (PSA) amplamente utilizado para o diagnóstico do 
cancro da próstata, podem ser avaliados em conjunto com outros 
biomarcadores relevantes, surgindo neste sentido a identificação e 
quantificação da enzima lactato desidrogenase (LDH), que recentemente 
tem sido sugerida como uma excelente ferramenta de prognóstico e 
monitorização do tratamento do mesmo tipo de cancro. Tendo em conta 
que ambos os biomarcadores são proteínas e que os fluidos humanos são 
matrizes muito complexas, os métodos atuais de identificação e 
quantificação apresentam pouca seletividade e podem conduzir a falsos 
positivos ou negativos. Neste sentido, torna-se fundamental desenvolver 
alternativas eficientes para a identificação e quantificação de vários 
biomarcadores tumorais presentes na mesma amostra. Para este efeito, 
avaliaram-se sistemas aquosos bifásicos (SAB) constituídos por líquidos 
iónicos (LIs) como uma técnica alternativa de extração e purificação de 
PSA e LDH a partir de fluídos biológicos sintéticos e reais. Neste 
trabalho identificaram-se SAB promissores capazes de extrair e 
concentrar PSA a partir de amostras de urina, e SAB capazes de extrair e 
purificar LDH a partir de amostras de soro humano, num único passo, 
permitindo portanto a sua identificação e quantificação de ambos os 
biomarcadores em fluidos humanos por métodos analíticos mais 
expeditos, tal como cromatografia líquida de alta eficiência por exclusão 
molecular (SE-HPLC). 
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Nowadays, prostate cancer is the third most common cause of death 
among men. Currently, there is no effective treatment when the tumor is 
diagnosed at an advanced stage. Given the high mortality rates 
associated with cancer, the identification and quantification of tumor 
biomarkers in human fluids and tissues have been the subject of intense 
research aiming more reliable diagnoses and to avoid excessive 
invasive treatments. In recent years, a special interest was also raised on 
the simultaneous analysis of several biomarkers for the same purpose, 
i.e., in order to make a more accurate diagnosis. Therefore, certain 
tumor markers, such as prostate specific antigen (PSA) widely used for 
the diagnosis of prostate cancer, should be considered together with 
other relevant biomarkers, like lactate dehydrogenase (LDH), which has 
recently been indicated as an excellent prognostic and monitoring tool 
of treatment of the same type of cancer. Considering the current 
methods for the quantification and purification of these biomarkers, and 
since both are proteins and are present in complex biological media, 
they usually exhibit low selectivity and may lead to false positives or 
negatives. In this context, it is crucial to develop efficient and selective 
analytical methods for the identification and quantification of several 
tumor biomarkers present in the same biological sample. For this 
purpose, aqueous biphasic systems (ABS) composed of ionic liquids 
(ILs) were investigated as an alternative extraction and purification 
technique for these biomarkers from synthetic and real biological fluids. 
In this work, novel ABS capable of extracting and concentrating PSA 
from human urine, and SAB capable of extracting and purifying LDH 
from human serum, in a single-step, were identified, allowing thus the 
identification and quantification of both biomarkers in biological fluids 
using more expedite analytical equipment, such as size-exclusion high-
performance liquid chromatography  (SE-HPLC).  
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1. General Introduction 
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1.1  Scope and objetives 
The accelerated pace of biomedical research faced in the past 50 years has resulted 
in the ability to alter cellular functions in predicable ways — providing the scientific and 
medical communities with innovative methods to detect and study diseases, as well as in 
the development of effective ways to treat serious medical conditions such as cancer (3).  
 Worldwide, prostate cancer (PCa) is one of the most common types of cancer being 
related with a high percentage of deaths among men (4). Early diagnosis is highly required 
to avoid these numbers. Biological molecules like biomarkers have many potential 
applications in oncology, including cancer screening, risk assessment, differential 
diagnosis, prognosis, and evaluation of response to treatment (5). Although the 
identification and quantification of cancer biomarkers can be helpful to improve the 
success rate of PCa treatment, many difficulties are associated to immuno(metric) assays 
kits due to their variation in specificity and binding affinity of the employed antibodies (6). 
Moreover, protein biomarkers secreted by tumors at very early stages of growth (when 
symptoms have not yet developed) appear at very low concentrations, a problem that needs 
to be bypassed by analytical methods (7).  
 Based on the aforementioned concerns, this work starts with an introduction 
referring to the prostate cancer epidemiology, followed by the understanding of the 
mechanisms that comprise the appearance and development of this disease. At the 
biomarker level, the key features of these biomolecules, and particularly for PSA and 
LDH, are highlighted to better understand their importance in prostate cancer. Finally, 
aqueous biphasic systems as alternative purification and concentration platforms are 
described.  
The main goal of this MSc thesis consists on the development of efficient methods 
to pre-treat biological fluids so that the detection/quantification of prostate cancer 
biomarkers could be achieved by more expedite and less-expensive analytical equipment 
aiming at increasing the rate of early-stage diagnoses. For this purpose, aqueous biphasic 
systems (ABS) composed of ionic liquids and organic salts were studied, both in the 
extraction and concentration of the biomarker prostate specific antigen (PSA) from urine 
samples and in the extraction/purification of the biomarker lactate dehydrogenase (LDH) 
from human serum. As demonstrated in this work, the development of these pre-treatment 
strategies to purify and concentrate biomarkers from human fluids allowed the use of  Size-
Exclusion High Performance Liquid Chromatography (SE-HPLC) for their identification 
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and quantification, representing thus a remarkable alternative to the commonly and 
currently used immunoassays that display several drawbacks (mainly high cost due to the 
use of specific antibodies, and false negatives and positives results due to other proteins 
interferences).   
 
1.2 Cancer update overview 
 
1.2.1 Epidemiology  
 Nowadays, and worldwide, cancer is the leading cause of death, with approximately 
14 million new cases each year (8). Just in 2012, 8.2 million deaths have been registered, 
being expected an increase up to 70% in the next two decades (9). The rate of death by 
cancer was found to be higher for men (205 per 100,000) than for women (165 per 
100,000) (10). For both, the highest rate recorded worldwide was found in Denmark with 
338 people per 100,000 being diagnosed with cancer in 2012. Comparing developed 
countries with developing countries, prostate, colorectal, female breast, and lung cancer 
rates are 2 to 5 times higher in the first type as a result of variations in an unequal set of 
risk factors and diagnostic practices. The opposite trend is true for cancers related to 
infections, such as stomach, liver, and cervical cancers (11).  
In Portugal, the cancer death rate is 246.2 per 100,000 individuals (10), being the 
prostate cancer (PCa), large bowel, lung and bladder the types of cancer with higher 
incidence, prevalence and mortality among men population (Figure 1.1) (12). PCa is the 
third most common type of cancer in men, in all Europe, North America, and some parts of 
Africa. It has been estimated that 1.1 million men worldwide were diagnosed with PCa in 
2012, accounting for 15% of the cancers diagnosed in men, with almost 70% of the cases 
(759,000) occurring in more developed regions (13).  
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Figure 1.1- Statistical evaluation of cancer distribution in Portuguese men population in 2012 (Adapted from 
(10)). 
1.2.2  Cancer: molecular mechanisms 
Cancer is caused by DNA mutations that are acquired spontaneously or induced by 
environmental injuries (14). A low percentage of cancers are hereditary, remaining the 
majority of cancer cases a result of genetic mutations that arise from a variety of causes: 
toxins, UV radiation and other environmental agents and lifestyle factors, such as lack of 
physical activity, unhealthy diet or excessive alcohol consumption or smoking (8). During 
cancer progress, additional somatic mutations and genomic arrangements usually tend to 
accumulate (15), as well as epigenetic changes, such as increases in DNA methylation and 
alterations in histone modifications, as well as the variation of expression or function of 
key genes that are responsible for regulating growth, survival and senescence events (14).  
 Neoplastic cells have genetic alterations that are heritable, passing through cell 
linage upon cell division. In fact, these cells gather conditions for evolution by Darwinian 
selection (16). Nordling and his co-workers (3), back in 1953, proposed that cancer was 
caused by a succession of mutations. After a quarter century of rapid advances on cancer 
research, it is now assumed that cancer is a disease involving dynamic changes in the 
genome (17). These knowledge allowed Hanahan and Weinberg (17), to suggest that the 
vast catalogue of cancer cell genotypes is a manifestation of essential alterations in cell 
physiology that collectively dictate malignant growth, known by the hallmarks of cancer 
(Figure 1.2).  
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Figure 1.2- Illustration of six cancer hallmarks originally proposed by Hanahan and Weinberg (Adapted 
from (15)). 
Like normal tissues, tumors require nutrients and oxygen to develop, as well as the 
ability to discharge metabolic wastes and carbon dioxide. Vascularization is essential for 
tumors to grow and is controlled by the balance between angiogenic and anti-angiogenic 
factors that are produced by tumor and stromal cells (14). If these cells have a deregulated 
control of cell proliferation they will proceed with adjustments of energy metabolism in 
order to complete cell growth and division (18). In normal tissues, cells control the 
production and release of growth promoting signals that instruct the cell to grow and 
divide; however, cancer cells use a number of strategies to drive their proliferation and 
become insensitive to normal growth regulators (14). In the cells cycle, tumors suppressors 
operate in order to limit the cell growth and proliferation. In general, when unbalanced 
expression occur it is verified an overproduction of growth factors along with cancer 
(Figure 1.3). A curious fact about cancer is that cancer cells develop alterations in their 
shape as well as in their attachment to other cells and to the extracellular matrix (ECM), 
reflecting thus local invasion, intravasion into blood and lymph vessels, transit through the 
vasculature, extravasation from the vessels and distant metastasis (18).  
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Figure 1.3 - Balance between growth factors and growth inhibitors; when growth factors are highly 
expressed, cancer occurs.   
Only in rare situations, cells emerge and exhibit unlimited replicative potential, 
termed as immortalization (19). In the absence of p53 — the key mediator of the response 
to dysfunctional telomeres — cell death and cell cycle arrest responses are mitigated. 
Additionally, the accumulation of neoplastic cells may result not only in the activation of 
growth-promoting oncogenes or inactivation of growth-suppressing tumor suppressor 
genes but also in the mutation of genes that regulate apoptosis and avoid the immune 
system of evading eradication (14). Based on the knowledge of these factors, advances in 
cancer molecular biology have identified new ways to inhibit the growth of cancer, leading 
to new, more selective and less toxic forms of cancer chemotherapy (20). 
 To understand cancer it is necessary to know how to distinguish its forms, and thus, 
the division of neoplasms into benign and malignant categories is based on a judgment of 
tumors clinical behavior. Benign neoplasms are, in majority, encapsulated by a fibrous 
connective tissue capsule, while malignant ones are invariably non-encapsulated (21). In 
addition to the proliferative neoplastic cells that make up their parenchyma, both benign 
and malignant neoplasms have supportive stroma, made up of connective tissue and 
vascular supply. The characteristics of both types of cancer are summarized in Table 1.1.  
Table 1.1 - Characteristics that allow to differentiate benign a malignant neoplasms (Adapted from (20)). 
Characteristics Benign Malignant 
Growth type Expansive Infiltrating 
Growth speed Slow Fast 
Stabilization Frequent Exceptional 
Mitoses Rare Numerous 
Evolution Local Local/General 
Metastasizing No Yes 
Spontaneous evolution Usually favorable Always fatal 
Evolution after removal No recurrences Common recurrences 
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1.3 Prostate cancer 
 
1.3.1 Diagnosis and molecular mechanisms 
 The majority of prostatic tumors, which have origin in prostatic epithelium, are 
within adenocarcinomas. The PCa progression is a process involving multiple molecular 
alterations, many of which can be reflected in changes of gene expression in the prostate 
carcinoma cells (22). Benign prostate hyperplasia (BPH), on the other hand, is the most 
common benign tumor found in men with age higher than 60 years-old (23). Men with 
early localized PCa often have no symptoms; yet, as cancer evolves in the gland, some 
urinary tract symptoms may develop, being commonly more associated with BPH (24). 
Prostatic carcinomas are typically diagnosed by a histological evaluation of prostatic 
tissue taken by biopsy or by transrectal ultrasound (TRUS) guided biopsies (25). PCa is not 
only addressed by the histological evaluation, but it is also supported based on PSA values 
in serum and local findings based on digital rectal examination (DRE), as it will be 
discussed below. The risk of development of PCa increases with age, and depends on other 
factors, such as ethnics, diet, levels of testosterone and its main metabolite, 5-
dihydrotestosterone, and family history (26,27). 
 Prostate is one of the accessory glands of reproduction, whereas its primary 
function is to secrete an alkaline fluid that is part of the ejaculate, which nourishes sperm 
and aids in its motility (28). The peripheral, central, transition, and fibromuscular are the 
four anatomic zones of prostate, with the peripheral zone comprising about 75% of the 
gland (29). Several studies already demonstrated that BPH usually develops in the 
transition zone, whereas 75% of PCa develops in the peripheral zone. The cytological 
characteristics of prostate adenocarcinomas include hyperchromatic, enlarged nuclei with 
prominent nucleoli and abundant cytoplasm (28, 29). The basal cell layer is absent in PCa, 
but present in normal glands and glands of BPH (30).  
 The progression of PCa can be described in terms of growth rate, hormone 
responsiveness, histology and metastatic ability (30). Some of the somatic alterations in 
PCa cells are genetic while others are epigenetic. However, both contribute to somatic 
genome alterations producing the cancer phenotype (31, 32). In fact, Singh et al. (33) 
reported, for the first time, the correlation between gene expression signatures and clinical 
outcomes with the intention to anticipate the clinical behavior of the disease. Years later, 
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True et al. (34), identified a 86-gene model capable of distinguishing low-grade from high-
grade cancers, being the first research group publishing a study demonstrating that gene 
signatures could be used for pathological staging of PCa.  
  Prostatic carcinoma is characterized by the silencing of the pi-class glutathione S-
transferase gene (GSTP1), which encodes a detoxifying enzyme (35). The silencing of 
GSTP1 results from aberrant methylation at the CpG island in the promoter-5’ and may 
render prostatic cells sensitive to carcinogenesis driven by inflammation and dietary 
factors (36). This loss of function occurs in the vast majority of cases of high-grade 
prostatic intraepithelial neoplasia and prostate cancers (37). As happens with many 
cancers, evidences show that telomere shortening may be a nearly universal feature of 
early-stage PCa and may promote chromosomal instability leading to the disease 
progression (38). From genes located on chromosome 8p, it stands out the NKX3.1 gene, 
being its product a prostate restricted homeobox protein that is involved in the regulation 
of prostate development. This gene is expressed in normal prostate epithelium and is often 
decreased in prostatic intraepithelial neoplasia (PIN) lesions and in prostate tumor cells. 
Posterior studies on chromosome 8p, have identified two small common deleted regions at 
8p23.1 and 8p21.3, which showed evidence linkage to hereditary prostate cancer (38). 
Moreover, alterations in the expression at the 8q24 locus have been observed, which 
includes the C-MYC proto-oncogene (39). This has been noted as one of the most common 
chromosomal abnormalities in PCa progression. A study carried out by Hawksworth et al. 
(39) revealed that higher levels of C-MYC mRNA are related to primary prostate tumors, 
and that the C-MYC locus is frequently amplified in advanced stages of PCa, but rarely in 
primary prostate tumors. In summary, the current knowledge on the PCa molecular 
mechanisms has contributed to the development and approval of various cancer biomarkers 
by the Food and Drug Administration (FDA) (40). 
 
1.4  Prostate cancer biomarkers 
 In the last years, the interest in the use of biological markers to evaluate the risk of 
future diseases has significantly increased (41). According to the National Cancer Institute, 
a biomarker is “a biological molecule found in blood, other body fluids, or tissues that is a 
sign of a normal or abnormal process, or of a condition or disease” (42). These different 
types of biomolecules can be used do predict, detect, diagnose, distinguish benign from 
malignant tumors, or one type of malignancy from another, and also be used for prognostic 
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(43). They can be detected by screening technologies like micro-RNA expression profiling, 
gene expression profiling, genome hybridization, proteomic profiling, molecular imaging, 
assessing tumor specific antibodies and circulating tumor cells (44). Molecular alterations, 
such as mutations, can be uncovered by using DNA sequencing, mass spectrometry based 
genotyping or mutation specific polymerase chain reaction (PCR). Although biomarkers 
have numerous advantages, variability is a major concern (43). Variability applies 
regardless of whether the biomarker represents an exposure or effect modifier, a surrogate 
of the disease, or an indication of susceptibility. For that reason, there is no biological 
biomarker completely reliable, especially in early detection and diagnosis, and a well-
established range is difficult to attain. However, a large number of biomarkers exists and 
that are currently used in clinical practice, being already approved by FDA (45).  
The management of prostate cancer has undergone several dramatic changes as a 
result of the evolution of biomarkers used in screening, detection and prediction of the 
disease (31). Human prostatic acid phosphatase (PAP) (or serum acid phosphatase (AP) 
was reported as the first serum biomarker of prostate cancer (31). Although AP, with 
elevated levels in more than 70% of the patients, was linked with early-stages prostate 
cancer, both AP and prostate-specific AP (PAP, its subtype) were later found to be not 
enough sensitive for screening (46,47). Only many decades later, the PSA screening was 
proposed and latter approved by FDA as a more sensitive and specific PCa marker (45).  
In 1999, Bussemakers et al. (48) were the first to publish their findings regarding a 
new prostate cancer–related gene, prostate cancer gene 3 (PCA3). Using the PCR method, 
authors demonstrated that this gene was overexpressed in prostate tumor tissues. In 2012, 
FDA also approved this biomarker for use in men in which PCa is suspected based on PSA 
levels and/or DRE and/or one or more negative biopsy results. In general, this assay 
comprises the determination of the levels of PCA3, PSA and RNA and is further based on 
the calculation of the ratio of PCA3 RNA molecules to PSA RNA molecules (PCA3 score) 
in post-digital rectal examination (DRE) urine specimens (49).  
Nowadays, the research on cancer biomarkers and their use in diagnosis is focused 
on serum, urine, and tissue samples to improve accuracy and response to current clinical 
challenges in the decision of undergoing biopsy, invasive therapies and to alter therapeutic 
strategies (50). Many new PCa biomarkers have been recently suggested to be 
concomitantly used with markers that are already well-established and used, since the use 
of a group of biomarkers instead of one is a step forward to avoid overdiagnosis and 
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overtreatment (51). One of these examples is TMPRSS2-ERG (Figure 1.4); the fusion 
between the transmembrane protease serine 2 (TMPRSS2) gene and the v-ets 
erythroblastosis virus E26 oncogene homolog (avian) (ERG) gene is the predominant 
variant in approximately 40% to 80% of PCa cases (50). Quantitative levels of TMPRSS2-
ERG in urine appear to be associated with clinically significant PCa. Moreover, the 
assessment of post-DRE urine TMPRSS2-ERG, in combination with urine PCA3, has 
shown to enhance the utility of serum PSA levels for predicting PCa risk and clinically 
relevant cancer on subsequent biopsy. On other hand, the dysregulation of PTEN, a tumour 
suppressor gene involved in cell cycle regulation, is consistently associated with poor 
prognosis in PCa (50). 
ERG Target Gene ERG Target Gene ERG Target Gene
Prostate cancer
ERG
ERG
TMPRRS2 ERG
ERG
 
Figure 1.4 Gene fusion events are recurrent in prostate cancer. TMPRSS2-ERG fusion results in the 
upregulation of ERG transcription which then exerts its effects by binding target gene promoter regions, 
further resulting on their activation or inhibition and in the generation of neoplastic phenotype (Adapted from 
(40)) 
The most important source of error associated to biomarkers seems to be the failure 
on identifying factors that may alter their levels in body fluids or tissue (43). Up to now, no 
biomarker has been established as an ‘‘ideal’’ cancer screening tool that can meet the 
diagnostic and prognostic simultaneously (52). The validation of new cancer biomarkers 
for efficient cancer diagnosis and prognosis is quite necessary and demanding (53). 
Although, the PSA is currently the most consensual biomarker in the diagnosis of prostate 
cancer. It is expected that, in the next few years, more tests will become available to help 
clinicians in the prediction of aggressive PCa (49). In this sense, optimized quantification 
methods for cancer biomarkers are amply required and these should be based on more than 
one biomarker to improve accuracy in diagnosis. 
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1.5 Prostate-specific antigen (PSA) as a prostate cancer biomarker 
 PSA is a serine protease, with 33 kDa, and belongs to the human kallikrein gene 
family (54). The kallikrein family belongs to the largest cluster of peptidases in the human 
genome, being located at the chromosomal region 19q13.3-q13.4 (55). PSA is secreted by 
the prostatic epithelium and the epithelial lining of the periurethral glands. Its main 
function consists on the liquefaction of the seminal coagulum to allow the release of 
spermatozoa by the preferential hydrolysis of arginine- and lysine-containing substrates 
(56,57). Outside its physiological role, PSA may participate in the process of proliferation 
of normal and abnormal cells, and in particular, in the tumoral growth of prostate cells 
through the degradation of the insulin-like growth factor binding protein 3 and 4 (58). PSA 
expression is regulated by the androgen receptor, whose activity has a fundamental role in 
prostate tissue development and progression of prostate cancer (55). 
PSA is a 237- residue glycoprotein with a single N-oligosaccharide chain linked to 
Asn61, close to the entrance of the catalytic cleft  and close to the kallikrein loop, but far 
from the dimer interface (59). This N-linked sugar-moiety, of N-acetylglucosamine 
(GlcNAc), comprises about 8% of the total mass and is the major sugar-chain structure of 
PSA (60). PSA comprises 92% of peptides and 8% of carbohydrates, whereas the 
carbohydrate fraction is constituted by 4.84% of hexoses, 2.87% of hexosamines, and 
0.25% of sialic acid (61). PSA also has in its composition His57, Asp102 and Ser195, 
sharing the catalytic triad characteristic of serine proteases; this catalytic site is conserved 
and located in a cleft between two β-barrels (59,62).  
 PSA is a glycoprotein that has several isoenzymes, two intact and nicked forms of 
PSA, in the isoelectric point (pI) range of 6.5–8 (63). This biomolecule is synthesized with 
a 17–amino acid leader sequence (preproPSA),  that is cotranslationally cleaved to 
generate an inactive 244–amino acid precursor protein (proPSA; Figure 1.5) (64). Normal 
secretory epithelium, surrounded by basal cells and a basement membrane, secretes 
proPSA into the lumen where the pro-peptide is removed by hK2 to generate active PSA, 
by the cleavage of the N-terminal between the arginine at position 7 and isoleucine at 
position 8 of proPSA (65).  
A fraction of the active PSA can diffuse into the circulation, where it is rapidly 
bounded by protease inhibitors (primarily alpha1-antichymotrypsin, ACT). Active PSA 
also undergoes proteolysis in the lumen to generate inactive PSA, which can enter the 
bloodstream and circulates in an unbounded state (free PSA). The majority (70% to 90%) 
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of PSA that enters the peripheral blood is intact and circulates as an 80- to 90-kDa complex 
with the protease inhibitor alpha1-antichymotrypsin (64). Minor amounts are complexed 
with other protease inhibitors, including alpha2-macroglobulin and alpha1-antitrypsin (64). 
 
Figure 1.5 - Structure of prostate-specific antigen (PSA) forms (64). 
The quantification of PSA in human fluids is a powerful tool for early PCa 
detection (67). The earliest report on the properties of antigens in the prostate is back to 
1960 and was reported by the American urologist Rubin Flocks (68). Only in 1980, PSA 
was quantified in blood and studied for clinical uses as a marker of prostate cancer (32). 
However, only six years later, FDA approved PSA test for prostate cancer screening (54).   
 Despite nearly 20 years of advances in molecular biology, only total PSA (tPSA) 
and free PSA (fPSA) measurements have found a relatively broad and growing clinical 
role in the management of prostate cancer patients (69). An annual screening of PCa is  
extremely recommended for men with 50 or more years old, and in African American men 
with more than 40 years old (because ethnicity is a relevant factor) (70). Men with 
clinically localized prostate cancer are considered ‘‘very low risk’’ if they have PSA levels 
< 10 ng.mL-1; men with ‘‘intermediate risk’’ have PSA values between 10 and 20 ng.mL-1 
in serum; and men with ‘‘high risk’’ of prostate cancer have PSA levels in serum > 20 
ng.mL-1 (71). More than in other cancer types, age is a significant factor that influences the 
PCa development and PSA baseline values. The serum PSA concentration seems to be 
directly correlated not only with the patient age but also with the prostatic volume, 
allowing the prediction of the disease stage and size of the tumor (72). PSA values > 4.0 
μg.L-1 in serum (and more recently > 2.5 μg.L-1) has been defined in the literature as 
abnormal and it is frequently used as a cut-off. The diagnosis of PCa is usually performed 
based in abnormal DRE results or findings of high concentrations of PSA in serum (72). In 
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general, it is accepted that the levels of PSA can be indicative of the cancer risk, as 
summarized in Figure 1.6. 
Total PSA
Total PSA 
<4.0 ng/mL
<2%
<2.5 ng/mL
< 2%
2.5-4.0 
ng/mL
18%
Total PSA 4-
10 ng/mL
25%
Total PSA 
>10 ng /mL
67%
 
Figure 1.6 -Probability of PCa by total PSA levels in serum (Adapted from (71)). 
 After the detection of high levels of PSA in human serum, active surveillance is 
reacquired to avoid radical treatment (73). For that, biopsy or MRI analysis are then 
performed, as well as continued PSA quantification (73).  However, PSA screening is still 
controversial because it leads to a significant number of false-positive results and to 
subsequent unnecessary biopsies and detection of clinically indolent tumors and 
subsequent overtreatment (67). Based on this information, a panel of diagnostic and 
prognostic biomarkers that could work in conjunction with PSA will be ideal (74). In this 
sense, new biomarkers, like lactate dehydrogenase, have been proposed in the past few 
years for PCa diagnosis and that can be included in the discussed biomarker panel (53). 
 
1.6 Lactate dehydrogenase as a cancer biomarker 
 Lactate dehydrogenase (LDH), EC1.1.1.27, is a NAD+-dependent enzyme of the 
oxidoreductases family, with a molecular weight between 115 kDa and 154 kDa (74). This 
enzyme catalyzes the last step of lactic fermentation, converting pyruvate to lactate (75). 
For this conversion, LDH presents an active center rich in hydrophilic and charged 
residues as glutamate, glutamine, aspartate, arginine and histidine (76). 
 LDH is usually present in the liver, cardiac muscle, kidneys, skeletal muscle and 
erythrocytes. It is composed of four polypeptide chains, each one encoded by a separated 
gene (M and H) (77), which associate into five different combinations of polypeptide 
subunits resulting in five molecular isoforms of LDH, and thus being found in different 
quantities depending on the originating tissue (78). However, some studies reported that 
the M form is usually present in anaerobic tissues, like skeletal muscle and liver (codified 
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by gene A), while the H form is typical of aerobic tissues, like cardiac muscle (codified by 
gene B), respectively located on chromosomes 11p15.4 and 12p12.2-p12.1.  
 It is well known that cancer and non-cancerous cells have different types of 
metabolism (79). In contrast to normal differentiated cells, which mainly perform 
mitochondrial oxidative phosphorylation to generate energy, most cancer cells resort to 
aerobic glycolysis, a phenomenon called "Warburg effect" (80). LDH levels and hypoxia 
are related by a tumor-driven angiogenesis pathway through the abnormal activation of the 
hypoxia inducible factor 1 (HIF-1) (76). Tumor hypoxia is enough to alter the gene 
expression of this factor and downregulate several genes, which encode for vascular 
endothelial growth factor, erythropoietin and many enzymes involved in glucose, iron, and 
nucleotide metabolism (81). A central player in the Warburg effect is lactate 
dehydrogenase-5 (LDH-5), which plays a crucial role in tumor maintenance, being thus 
considered a cancer biomarker (81). 
 According to the American Cancer Society, LDH is used as a cancer biomarker for 
germ cell tumors (82). Over recent years, the LDH use has undergone a high clinical 
importance being tested as a biomarker for myeloma, lung cancer, osteosarcoma and 
kidney cell carcinoma (83-86). The normal levels (healthy men) range between 100 and 
300 U.L-1, while levels higher than 300 U.L-1 are usually associated with cancer (86). 
Although total LDH levels in blood may be a diagnostically meaningful parameter in 
cancer patients, the clinical significance of serum isoenzymatic patterns of LDH is still 
under discussion (81). On the other hand, Nishikawa et al. (87) proposed that the 
determination of LDH isoenzymes in the urine might be useful in diagnosing urinary tract 
malignancy, including early stage ones. Nevertheless, it is known that LDH-5 levels in 
urine or body fluids can be altered, especially elevated, when bacterial infections occur 
(81).   
 Studies on LDH isoenzymes have led to the conclusion that since certain diseases 
of the prostate gland have different isoenzyme distributions, LDH isoenzymes may 
distinguish PCa from BPH (88). LDH-5 levels increase in prostate cancer and LDH-1 
decreases, while in BPH the contrary behavior is observed (88). Since LDH levels in 
presence of prostate cancer are rarely increased in early stages, LDH was tested for 
assessment of prognosis, therapeutic efficacy and evaluation of symptoms (89). In fact, 
some studies have reported that LDH is an excellent prognostic indicator for PCa patients 
with bone metastasis (90,91). Other studies referred that LDH-5 overexpression is 
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significantly linked to highly proliferating prostate carcinomas and can be used to monitor 
improvements in radiotherapy (92). It was also demonstrated that LDH levels and 
circulating tumor cells (CTC) count form a biomarker panel for castration-resistant 
prostate cancer (CRPC) (93). This biomarker panel proved to have high discriminatory 
power being thus an effective tool for discrimination between high-risk and low-risk 
patients with CRPC (94). More recent investigations stated that serum LDH high levels are 
associated with poor survival of patients with solid tumors, and could be used as a cost-
effective prognostic biomarker in terms of prognostic of metastatic carcinomas, including 
prostate cancer (95). As a whole, the quantification of LDH seems to be advantageous 
when combined with PSA determination in biological samples and can improve the 
accuracy of PCa diagnosis.  
 
1.7  Complex matrix handling 
 
1.7.1 Stability of LDH, and Total and Free PSA during Sample Storage 
 The problems encountered during analysis of complex biological samples are 
usually described as “matrix effects” (96). Complex samples, such as blood, display major 
barriers towards biomarkers discovery and their quantification. The main problem 
comprises the quantification of extremely low abundance (concentration) of the candidate 
markers in blood, which usually exist below the detection limits of conventional analytical 
techniques. In addition, the high abundance of resident proteins in blood, such as albumin 
which represent more than 50% of circulating plasma proteins, can mask the identification 
of rare biomarkers (97,98). The third challenge for biomarkers identification/quantification 
relays on the rapid degradation of the low abundance biomarkers - mainly because blood 
contains proteases which activity is enhanced when samples are collected (99). To handle 
these samples it is important to first remove the proteins content, which can be denatured 
using acids or heat, or ultra-filtration using cut-off membranes (100). Another possibility 
consists on the use of organic solvents such as trichloroacetic acid (TCA)/acetone mixtures 
(101).  
 Urine represents a way to perform non-invasive quantification of biomarkers for the 
early detection and prediction of prostate cancer prognosis (102). Urine contains a complex 
mixture of proteins, urea and high amounts of some ionic components (103). However, in 
urine samples, the variability of results can occur, especially in the presence of a large 
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plethora of components, such as organic compounds and electrolytes, and different pH 
values which can affect antibody binding and the assay performance (104). Recently,  
Struck-Lewicka et al. (105) demonstrated that urine metabolites are altered in prostate 
cancer, a result of the urea and tricarboxylic acid cycle, amino acid and purine metabolism, 
which play a crucial role in the pathogenesis of the disease. Therefore, the future 
perspectives in cancer biomarker detection fit within the development of an efficient 
detection platform with high sensitivity, versatility, high-throughput and capability to 
concentrate and isolate biomarkers.  
In addition to matrix effects, the stability of cancer biomarkers, which are mainly 
proteins, plays a vital role. For instance, the LDH activity is dependent upon the storage 
temperature, storage medium and technique used for freezing (106). Some studies 
indicated a cold lability of the slower isoforms, e.g. LDH-4 and LDH-5, in both tissue 
homogenates and cord blood serum, with a greater loss of activity at -10°C than at 4°C 
(107). Shain et al. (108) evaluated the effect of storing human plasma and extracts of 
prostate at -90 °C on the activity of lactate dehydrogenase and isoenzyme distribution. 
Authors reported that these preparations can be thawed only once at 2 to 4 °C, and that 
they could be stored for as long as 165 days at -90 °C with no changes in isoenzyme 
distribution (108). Regarding PSA, parameters like pH and temperature may influence the 
stability of fPSA isoforms (109). Biological samples containing PSA should be stored at 
4°C and analyzed within 8 h after collection or at -70°C and at pH of 5.5 for latter analysis. 
For tPSA, it was proved that it is stable at room temperature for 24 h, for almost a week 
when stored in a refrigerator at 4°C, and for 1 month at -20°C (109). However, this is not 
valid for fPSA since it is the most thermolabile isoform (109).  
 
1.8  Identification and quantification of PSA and LDH by analytical 
methods  
 Since LDH and PSA biomarkers are primarily found in blood, and  sometimes in 
urine at low abundance, features of analytical methods such as sensitivity, specificity and 
accuracy are critical to improve the identification and quantification of cancer biomarkers 
(33). In 1980, it was developed for first time, the enzyme-linked immunosorbent assay 
(ELISA) method for quantification of PSA (112).  Since then, many other assays have been 
developed, not only for PSA, but also for the respective isoforms being currently 
commercially available (113,114). Although the ELISA method is extensively used in 
 18 
 
routine clinical diagnostics, many challenges remain to improve, such as the increase of the 
method sensitivity, accuracy and reproducibility as well as its high cost (52). Usually, all 
commercial immunoassays, like the Acess Hybritech PSA assay, consist on the incubation 
of monoclonal anti-PSA antibodies for further binding to PSA in serum samples (110). 
PSA purification/fractionation can also be performed by liquid chromatography methods 
and by recently developed electrochemical biosensors (60). On the other hand, the LDH 
detection is usually performed with colorimetric and chromatographic methods, it can be 
also quantified by electrochemical methods (120-122). Tables 1.2 and 1.3 present a 
summary of the techniques and methods commonly applied in the identification and 
quantification of PSA and LDH.   
 
Table 1.2  Comparison of literature methods for the purification and quantification of PSA in different 
matrices. 
Purification/Concentration method Isoform Matrix Sensitivity (ng.mL-1) Ref. 
Immunoassay 
ELISA PSA Serum 0,1935  (115) 
Sensitive rapid tandem bioluminescent 
enzyme immunoassay (BLIA) 
PSA/ACT Serum 0,3 (116) 
Hybritech PSA assay PSA/ACT Serum 1800 (117) 
Chromatography 
Liquid chromatography (LC) coupled 
with tandem mass spectrometry (MS-
MS) 
PSA Serum 1  
(118) 
 
Biosensors 
Surface plasmon resonance (SPR)  PSA/ACT Serum 18.1  (119) 
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Table 1.3 Comparison of literature methods for the purification and quantification of LDH in different 
matrices. 
 
Even though the methods listed in Tables 1.2 and 1.3 are currently used, they display 
some disadvantages. Electrochemical/electrical detection strategies are currently available 
for both PSA and LDH, and in general they display a high sensitivity and simplicity 
combined with the use of miniaturized hardware (52). However, the application of 
impedance biosensors has been limited by their sensitivity to nonspecific adsorption, which 
often limits the applicability of these biosensors to complex matrices (52). Analytical 
techniques, like electrophoresis, are suitable to use since they simultaneously separate 
thousands of proteins and allow the comparative protein profiling between different crude 
biological samples (123). Nevertheless, they are incapable of detecting the majority of 
protein components found in low abundance in these samples due to their low detection 
limits. High-performance liquid chromatography (HPLC) presents high versatility, being 
able to detect biomarkers in the range from picograms to multigrams, combining speed, 
reproducibility, and sensitivity (34). However, despite these advantages, HPLC exhibits a 
limited effectiveness in bioanalytical applications, namely the lack the sensitivity required 
to quantify low levels of endogenous substances. Moreover, most of the times, HPLC 
requires complex and time-consuming samples purification and derivatization steps, which 
increases the cost and time effectiveness (124,125). For HPLC analysis it is required the 
use of special kits to eliminate highly abundant proteins and to allow the 
identification/quantification of low abundant biomarkers (123,126). An example of these 
Purification/Concentration method Isoform Matrix Sensitivity  Ref. 
Chromatography 
Flow injection analysis with fluorimetric 
detector 
LDH Tissue 0.1x10-3 U.L-1 (120) 
Reversed-Phase Liquid 
Chromatography Tandem Mass 
Spectrometry 
L-LDH Plasma 0.2 µmol.L-1 (114) 
Reversed-Phase Liquid 
Chromatography Tandem Mass 
Spectrometry 
L-LDH Urine 8.1 nmol.mmol-1 (114) 
Electrophoresis 
Isoelectric focusing LDH-5 Tissue 10 U.L-1 (121) 
Biosensors 
Electrochemical biosensor with 
nanointerface 
L-LDH Tissue 4.73 nmol.L-1 (122) 
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kits is the Cibacron blue F3GA based- and antibody-related methods. Evidences show that 
Cibacron blue F3GA based-resin method removes not only albumin from serum samples, 
but also every proteins having the same pI (123). Finally, colorimetric assays, as those 
used in LDH quantification, display low sensitivity and accuracy (124). 
Based on the summarized information presented above, it is mandatory the 
development of alternative extraction/concentration techniques that can be coupled to 
analytical methods of higher accuracy and lower cost in order to reduce the costs 
associated with biomarkers quantification and sample purification, so that cancer diagnosis 
can be improved.  
 
1.9 Aqueous biphasic systems as platforms of concentration and 
extraction of proteins 
 Aqueous biphasic systems (ABS) were originally discovered by the observation of 
the formation of two liquid phases by dissolving gelatin and agar in aqueous media (127). 
Only years later, Albertsson demonstrated that ABS can be formed with two polymers or a 
polymer and a salt in aqueous media, and that these systems can be used in the extraction 
and purification of proteins, viruses, cells, among others (128).    
 ABS are mainly composed of water and are thus more biocompatible and more 
environmentally benign than volatile organic solvents commonly used in the extraction of 
value-added compounds from aqueous media (129). ABS can be classified in 
polymer/polymer-, polymer/salt- and salt/salt-based systems, i.e., two solutes structurally 
different, and both water-soluble, that separate into two coexisting phases above a given 
concentration: one of the aqueous phases will be enriched in one of the solutes while in the 
other phase there is prevalence for the second polymer or salt (130). The phase diagrams of 
ABS are usually determined in advance as they provide the necessary information about 
the minimum concentration of each component required for the formation of two phases, 
and the concentration of the components in the top and bottom phases, as well as the 
volume or weight ratio of the two phases (35). Figure 1.7 shows an example of a ternary 
phase diagram of an ABS, and where the binodal curve and three mixture compositions at 
the biphasic region (X, Y and Z) are presented. The mixtures X, Y and Z are along the 
same tie-line (TL) meaning that all initial mixtures present the same top phase composition 
(TIL, TSalt) and the same bottom phase composition (BIL, BSalt). 
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Figure 1.7- Schematic representation of an ABS phase diagram: C = critical point; T = composition of the 
top phase; B = composition of the bottom phase; X, Y and Z = mixture compositions at the biphasic region; 
Fc: concentration factor on the top phase (Adapted from (35)). 
 
 Since proteins are complex molecules which readily undergo denaturation and lose 
their biological activity when in contact with some polymers, salts or organic solvents, 
ABS are a biocompatible method of extraction (132). Nowadays, the ABS application in 
the separation of biomolecules has been amply reported in the literature, especially with 
ionic-liquid-(IL)-based ABS (131,132). In particular, IL-based ABS have been extensively 
studied as alternative methods for the extraction and purification of several proteins, such 
as bovine serum albumin, papain, lysozyme, trypsin, myoglobin, peroxidase, cytochrome 
c, γ-globulins, hemoglobin, and ovalbumin, without compromising the enzymatic activity 
or the protein stability (130, 131, 132).  
 Pei and co-workers, in 2009, demonstrated that it is possible to extract proteins, 
with 100% extraction efficiencies obtained in a single step, using ABS composed of ILs 
and salts (132). Authors also demonstrated by UV spectroscopy that chemical interactions 
between BSA and IL do not occur and there are no changes in the protein conformation 
(132). Although the extraction of proteins using IL-based ABS can serve as a guideline for 
the use of these systems in the extraction of enzymes, it must be recognized that the 
catalytic activity is a key parameter for the success of enzymes extraction (130). Therefore, 
it is mandatory to ensure that the interaction between the IL in the aqueous solution and the 
enzyme are balanced, meaning that they must have a strong ability of dissolving enzymes, 
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but not strong enough to break the structure and/or interact with the active site of the same 
(130). More recently, Du et al. (134) reported the use of ABS composed of [C4mim]Cl and 
K2HPO4 for the extraction of proteins from biological samples, namely human urine, 
thereby increasing the possibility of ABS research for clinical use, particularly in clinical 
diagnosis. Passos et al. (135), later contributed to the advance in research of ABS, by 
concentrating endocrine disruptors from biological fluids up to 100 times in a single-step, 
using various ILs and K3PO4. More recently, ABS formed by phosphonium-based ILs have 
shown the ability to not only extract proteins of interest, but also to selectively denaturate 
proteins like albumin from complex matrices (136) 
, encouraging thus the investigation of this type of systems for the extraction, purification 
and concentration of cancer biomarkers from biological fluids.  
 Considering the advantages of IL-based ABS stated before, this work aims the 
application of phosphonium-based ABS in the concentration and purification of prostate 
cancer biomarkers from synthetic samples and finally with human fluids, so that more 
expedite and less expensive equipment for their identification/quantification can be used. 
Both PSA and LDH cancers biomarkers are investigated in this work envisaging the 
development of more accurate diagnosis of PCa by the use of two biomarkers in two 
different types of fluids, instead of one biomarker and one type of human fluid as currently 
carried out.  
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2.1  Introduction 
The discovery of room-temperature ionic liquids (ILs) was made by Paul Walden in 
1914 (137). However, only in 2003, Rogers and co-workers have proposed ABS composed 
of ionic liquids (ILs) and inorganic salts as alternatives to systems mainly composed of 
polymers (138). When a salt is added to an aqueous solution of an IL, there is the 
formation of two phases, one enriched in the IL and the other mainly composed of water 
and salt, due to the preferential hydration of the salt ions which induce the ILs salting-out 
from aqueous media (130).  
 ILs are a class of compounds generally composed of large organic cations and an 
anion that can be organic or inorganic (139). Generally, these salts have a melting point 
below 100° C and exhibit reduced electrostatic forces, which difficult the formation of a 
regular crystalline structure. Due to the large number of potential cation-anion 
combinations, ILs are also known as “designer solvents”. ILs can be classified into 
imidazolium-, pyridinium-, pyrrolidinium-, phosphonium-, sulfonium-based, among others 
(140,141). Despite the immense versatility inherent to the cation–anion permutations in 
ILs, most ABS have been attempted using imidazolium-based compounds; however, more 
recently, phosphonium-based ILs have emerged as potential alternatives in ABS formation 
and where studied in proteins extraction (130). The capacity of phosphonium-based ABS 
as prospective extraction media in biotechnological processes was also demonstrated by 
the high partition coefficients obtained with hydrophobic biomolecules (142). 
           The first reports of phosphonium-based ILs dates from the 70s, when Parshall (141) 
reported the synthesis of phosphonium-based ILs using stannate and germinate salts. 
Phosphonium-based ILs display some advantages, mainly higher thermal and 
electrochemical stabilities when compared with the largely investigated imidazolium-based 
counterparts (142). The lack of acidic protons turns them more stable, thus not reacting 
under reductive or alkaline conditions (143). Since these IL are less dense than water, they 
might be beneficial in several setups involving the separation of aqueous layers. Moreover, 
Louros et al. (144) reported that phosphonium-based ILs are more effective in the creation 
of ABS compared to the typical imidazolium-based class, meaning that lower amounts of 
ILs are required for their application in extraction, concentration and purification 
approaches.  
Despite the evidences referred before, the use of IL-based ABS for the extraction, 
concentration and purification of cancer biomarkers from human fluids has not been 
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reported in the open literature. Even so, IL-based ABS seem to be a good alternative as a 
pre-treatment strategy of human fluids to allow the use of more accessible equipment for 
the quantification of cancer biomarkers in clinical laboratories. This requirement is mainly 
due to the high complexity of human fluids which inherently require their pre-treatment 
before the identification/quantification of target biomolecules, ie, to reduce interferences of 
other analytes. Protein purification methods are usually time consuming, expensive and 
employ volatile organic compounds hazardous to human health, environment and highly 
susceptible biomolecules such as proteins (145). In this sense, IL-based ABS also emerge 
as a more friendly alternative, since they are mainly composed of water and it is possible to 
maintain the pH of these systems by the addition of a proper biological buffer, allowing to 
conserve the stability of proteins.  
The determination of PSA levels in human fluids has become a standard practice 
for prostate cancer recurrence monitoring. PSA is typically undetectable by most assays 
after surgery, and it is generally agreed that undetectable post-surgical PSA over time is 
indicative of a good prognosis (146,147). As long as PSA remains undetectable, the patient 
can be assured that there is no biochemical evidence of cancer recurrence. Indeed, the less 
sensitive the assay, the longer this assurance can be offered, while in fact, PSA could be 
present, yet below detectable levels (148). Nowadays, in clinical laboratories, total and free 
PSA are quantified by immunoassays, mainly by the chemiluminescent microparticle 
immunoassay (CMIA) (149). Although, immunoassays are susceptible to interferences like 
cross-reactivity with other drugs and metabolites, reaction with heterophilic antibodies, and 
influence of endogenous factors, like hematocrit or albumin, in the case of serum analysis 
(150). Interfering substances may lead therefore to false positive or false negative results.. 
In addition to CMIA, only one more method to quantify PSA is available, namely the 
Abbott Diagnostics and Quantitative Microsphere System (QMS™), having a sensitivity 
below 1μg.L-1, and reported as to offer adequate accuracy and precision (151).  
Since the methods described before require expensive equipment setup, the 
acquisition of antibodies and are usually time-consuming, alternative techniques are 
mandatory. IL-based ABS represent a potential alternative for the pre-treatment of samples 
before PSA analysis. ABS are easy to implement, of low cost and capable of simultaneous 
act as extraction, purification and concentration platforms. Indeed, recent reports have 
shown that IL-based ABS can be used to concentrate biomolecules of interest from 
biological fluids up to 100-times (135), and persistent pollutants from aqueous streams up 
 27 
 
to 1000-fold (from ng.L-1 to µg.L-1) in a single-step (152). After the pre-treatment of 
human fluids with IL-based ABS, samples are envisaged to be simpler analyzed by more 
expedite equipment, such as SE-HPLC, avoiding thus the use of more expensive 
immunoassays. 
In this section, IL-based ABS were used to simultaneous extract and concentrate 
PSA from synthetic and human urine samples in order to increase their values up to 
concentrations that can be quantified by SE-HPLC with an UV or DAD detector. Since 
human urine samples are not rich in proteins, in this section, the purification step was not 
attempted. Since the cut-off value of PSA in urine is 150 ng.mL-1 (71) concentration 
factors of circa 250-fold must be studied in order to reach the limits of detection of more 
expedite equipment, like HPLC. As a first attempt, methods were optimized with synthetic 
samples and then applied to real human urine samples. 
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2.2  Experimental Section 
 
2.2.1  Chemicals 
The aqueous biphasic system studied in this section is composed of potassium 
citrate tribasic monohydrate, C6H5K3O7∙ H2O, > 99 wt% pure, from Sigma-Aldrich and the 
ionic liquid tetrabutylphosphonium chloride ([P4444]Cl), > 96 % pure, from Cytec Ind.. The 
chemical structure of the IL studied is represented in Figure 2.1. For HPLC analysis, 
sodium phosphate monobasic (NaH2PO4, purity: 99- 100.5%), sodium phosphate dibasic 
(Na2HPO4
. 7H2O, purity 98.2- 102.0 %) and sodium chloride (NaCl) were used to create 
the phosphate buffer solution at pH = 7. PSA dilutions were made by using phosphate 
buffered saline (PBS) aqueous solutions, 100 wt% pure from Sigma-Aldrich. Pure PSA, 
purity ≥ 95%, was obtained from Sigma-Aldrich Chemical Co.. 
 
 
Figure 2.1 Chemical structure of the studied IL: [P4444]Cl. 
 
 
2.2.2  Biological samples 
For the PSA quantification, 10 urine samples of random healthy patients were 
collected. The urine samples used were the first of the day. All samples collected belong to 
male individuals with ages between 20 and 30 years-old.  
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2.2.3 Phase diagrams, tie-lines and concentration factors of 
PSA using synthetic samples 
          The binodal curve of the studied ABS was taken from the literature (153), 
determined thought the cloud point titration method at 25 (±1) ºC and atmospheric pressure 
(Appendix A). The experimental procedure adopted by Passos et al. (153) consisted in the 
repetitive drop-wise addition of the aqueous salt solution (C6H5K3O7) into the aqueous 
solution of IL until the detection of a cloudy (biphasic) solution, followed by the dropwise 
addition of water until the observation of a limpid (monophasic region) (153). All the 
calculations considering the weight fraction of the phase-forming components were carried 
out discounting the complexed water in the commercial citrate-based salt. All additions 
were made under constant and controlled stirring and the ternary system compositions 
were determined by weight quantification of all components added within ± 10-4 g.  
The respective tie-lines were then determined for this phase diagram, by the 
gravimetric method originally proposed by Merchuk et al. (154). For this purpose, a 
selected mixture at the biphasic region was chosen and prepared by weighting the 
appropriate amounts of IL+ salt + water and further stirred. The mixture was submitted to 
centrifugation for 10 min at 3500 rpm and at controlled temperature of 25 (±1) ºC and 
subsequently left in equilibrium at 25 (±1) ºC for 10 minutes to guarantee the equilibration 
of the coexisting phases. Lastly, the compositions of bottom and top phases, as well as the 
overall system composition were determined by the level-arm rule.  
Experimental binodal curves were fitted by using equation. (1):                              
𝑌 =  𝐴 exp⁡[ 𝐵𝑋0.5 −  𝐶𝑋3 ] 
                                                                          (1) 
where Y and X represent the IL and salt mass fraction percentages, respectively, and A, B 
and C are constants obtained by regression of the experimental binodal data.  
Each individual tie-line was determined according the solution of the following 
system of four equations (2-5), and four unknown parameters (YT, YB, XT and XB):  
𝑌𝑇 = 𝐴 exp[(𝐵 × 𝑋𝑇
0.5) − ( 𝐶 × 𝑋𝑇
3)] 
                                                                       (2) 
𝑌𝐵 = 𝐴 exp[(𝐵 ×  𝑋𝐵
0.5) − ( 𝐶 × 𝑋𝐵
3)] 
                                                                     (3) 
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𝑌𝑇 =
𝑌𝑀
𝛼
 −  
1 − 𝛼
𝛼
×  𝑌𝐵  
                                                                                     (4) 
𝑋𝑇 =
𝑋𝑀
𝛼
 −  
1 − 𝛼
𝛼
×  𝑋𝐵  
                                                                                 (5) 
where in equations (2-5), T, B and M designate, respectively, the top phase, bottom phase 
and initial mixture; X represents the mass fraction of the inorganic salt, Y represents the 
weight fraction percentage of ILs and α is the ratio between the mass of the top phase and 
the total mass of the mixture experimentally determined. A, B and C are the constants 
obtained by the fitting of the experimental binodal curve by equation (1). 
 Each tie-line length (TLL) was determined through the application of the following 
equation:  
𝑇𝐿𝐿 =  (𝑋𝑇 − 𝑋𝐵)2 − (𝑌𝑇 − 𝑌𝐵)2 
                                                         (6) 
  In the studied system, the IL-rich phase corresponds to the top phase while the 
bottom phase is mainly composed of the organic salt and water.  
  
2.2.4   PSA extraction efficiency of IL-based ABS 
         The ternary mixtures composition used in the partitioning experiments were chosen 
based on the phase diagram of the IL+ salt+ H2O system used (153). The mixture point 
chosen in the biphasic region of the phase diagram was 30 wt% IL + 40 wt% salt + 30 wt% 
H2O. All ABS were performed for a final weight of 50 g.  Aqueous solutions of pure PSA, 
at concentrations of circa 150 ng.mL-1, were used as the “water” added to each ABS. Each 
mixture was vigorously stirred, centrifuged for 10 min at 3500 rpm and at 25 (± 1) °C, to 
reach the complete PSA partitioning between the coexisting phases.  
After a careful separation of the phases and their weight, the amount of PSA in each 
phase was quantified by SE-HPLC (Size Exclusion High-Performance Liquid 
Chromatography). Each phase was diluted at a 1:10 (v: v) ratio in a phosphate buffer 
solution before injection. A Chromaster HPLC (VWR, Hitachi) coupled to a DAD detector 
was used. SE-HPLC was performed with an analytical column (8 mm × 300 mm), Shodex 
Protein KW- 802.5. A 100 mM phosphate buffer in Milli-Q water (mobile phase) was run 
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isocrastically with a flow rate of 0.5 mL min -1. The temperature of the column and auto-
sampler was kept constant at 25 ºC. The injection volume was of 25 µL. The wavelength 
was set at 280 nm. The salt and IL interferences with the method of quantification were 
also verified and control samples were regularly analysed. 
The percentage extraction efficiency of PSA, EEPSA %, is the percentage ratio 
between the amount of protein in the IL-rich aqueous phase to that in the total mixture, and 
is defined according to equation (7): 
 
𝐸𝐸𝑷𝑺𝑨% =
[PSA]
𝐼𝐿 
× 𝑤𝐼𝐿
[PSA]
𝐼𝐿
× 𝑤𝐼𝐿 + [PSA]𝑆𝑎𝑙𝑡 × 𝑤𝑠𝑎𝑙𝑡
 
     (7) 
  
where [PSA] is the protein concentration, and wIL and wsalt are the weight of the IL-rich 
and salt-rich aqueous phase, respectively.   
To study the concentration factors achievable with the studied ABS, a long TL 
was chosen and several extractions were carried out at different initial compositions along 
the same TL, corresponding to different concentration factors, yet maintaining the 
composition of each phase. After the selection of the most appropriate TL, a weight 
balance approach was used to define the weight fraction of each phase-forming 
component, namely [P4444]Cl and C6H5K3O7, to be used in each extraction corresponding 
to a given concentration factor.  
The percentages of ionic liquid and salt required in each of these extractions 
resulted in the desired concentration factor, defined by equation (8), 
𝐶𝐹 =
𝑤𝐻2𝑂
𝑤𝐼𝐿
 
          (8) 
where wH2O and wIL correspond to the weight of the aqueous solution added containing 
PSA and the weight of the IL-rich phase (in which the protein is enriched) in the ABS. 
ABS were prepared first using the theoretical weight percentages of salt, IL and 
solution containing PSA, provided by the lever-arm rule, to select a mixture that could 
allow a maximum concentration factor of 250-fold. The ternary mixtures were prepared, 
firstly as control without PSA, and further by adding an aqueous solution with a PSA 
concentration equal to the cut-off value found in urine for PCa, namely 150 ng.mL-1 (71). 
ABS were prepared with appropriate weight percentages aiming to achieve 5, 20, 50, 100, 
150, 200 and 250-fold concentration factors. Each mixture was vigorously stirred, 
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centrifuged for 10 min and left to equilibrate for 10 min at 25 (± 1) ° C.  The phases were 
carefully separated and weighted, and PSA was quantified by SE-HPLC in each phase. The 
predicted CF was then confirmed according to equation (8). It should be remarked that the 
lever-arm rule allows to determine the concentration factor achievable by the studied 
system, i.e., the change in the volume/weight of each phase along the same TL. Different 
initial compositions along the same TL have the same composition of each phase, 
compensated by a change in volume/weight of the phases.  
 
2.2.5  SE-HPLC analysis of real samples 
The adequacy of the developed methods to extract and concentrate PSA was then 
investigated with real human urine samples.  Before the ABS preparation, a PSA solution 
of 1000ng.mL-1, in PBS buffer, was used to dilute PSA in the urine sample, to achieve a 
final concentration of 150 ng.mL-1. Thereafter, appropriate amounts of IL and salt were 
added to reach the initial mixture compositions selected that allow a CF of 250-fold. All 
ABS were performed for a final weight of 50 g. After obtaining the ABS, a careful 
separation of the phases was performed and their weight was determined. The amount of 
PSA in each phase was quantified by SE-HPLC, by the procedures described before.   
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2.3 Results and discussion 
 
2.3.1 Phase diagrams, tie-lines and concentration factors of 
PSA using synthetic samples 
The ternary phase diagram of the studied ABS was taken from the literature (153). 
The experimental weight fraction data and the referred phase diagram are presented in 
Appendix A. In the studied ABS, the top phase corresponds to the IL-rich phase, while the 
bottom phase is mainly composed of citrate-based salt and water. As evaluated in a 
previous work (1), for the cation core effect, ILs with the cation [P4444]
+ show the highest 
ability for ABS formation when compared with imidazolium-, pyridinium-, and 
pyrrolidinium-based ILs (1). The same trend was evidenced by Sintra et al. (155) in their 
study with ammonium-, phosphonium-, cholinium-, imidazolinum- and pyridinium-based 
ILs and where the potassium citrate buffer (C6H5K3O7/C6H8O7) at pH 7 was used instead 
of potassium citrate. [P4444]Cl, being a quaternary phosphonium-based cation IL, presents a 
high ability to form ABS, since its composed of four butyl chains which are responsible for 
its higher hydrophobicity (1).  On the other hand, being the citrate-based salt composed of 
a trivalent charged anion, it is a strong salting-out species according to the Hofmeister 
series (36), promoting therefore the preferential exclusion of the IL to the opposite phase 
(37).  
For the studied systems the experimental binodal data were also fitted by the 
empirical relationship described by equation (1) by Passos et al. (153) . The regression 
parameters are presented in Appendix A. The experimental tie-lines, determined in this 
work, along with their respective length, are reported in Table 2.1.  
 
Table 2.1 - Weight fraction percentage (wt%) of the initial mixture and of the coexisting phases, and 
respective values of TLL. 
Weight fraction composition/ (wt%)  
IL + C6H5K3O7 + water 
IL YT % XT % YM% XM% YB % XB % TLL 
[P4444]Cl 69.01 3.46 30.16 30.44 0.61 50.94 93.35 
81.26 2.32 29.53 39.36 0.11 60.43 99.81 
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Both tie-lines obtained for this system, as well as the respective binodal curve, are 
depicted in Figure 2.2. The pH values of this system are in the alkaline region (pH 8–10) 
due to the use of the citrate-based salt. Even though, no denaturation or aggregation of 
PSA were observed during the SE-HPLC assays.  
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Figure 2.2 - Phase diagram for the system composed of [P4444]Cl+ C6H5K3O7 + H2O at 25ºC and atmospheric 
pressure (in wt%) (153) and respective TLs. The experimental binodal curve was adjusted using equation (1). 
To verify the ability of the [P4444]Cl + C6H5K3O7 + H2O system to reach several 
concentration factors, different initial mixture compositions along the same TL were tested 
as illustrated in Figure 2.3. After validation of the experimental CF achievable with pure 
water, the same ABS were tested with aqueous solution of PSA at 150 ng.mL-1.  
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Figure 2.3 - Different compositions along the same TL for the system [P4444]Cl + C6H5K3O7 + H2O which 
allow to achieve different CF values 
 
CF were confirmed by weighting both the bottom and the top phase and by the 
application of equation (8). The capacity of the mixture to achieve the 250-fold CF was 
proven, allowing to reduce the volume of the IL-rich phase to a minimum capable of 
concentrate PSA 250 times and allowing, at the same time, its quantification by SE-HPLC. 
For the experiments with PSA, all CF tested were also achieved (Appendix B), 
demonstrating the ability of the system to extract and concentrate PSA in a single-step up 
to 250-fold.  
The HPLC chromatograms of the IL- and salt-rich phase for a CF of 250 are shown 
in Figure 2.4. The PSA retention time is between 12 and 14 minutes, agreeing with the 
retention time of a standard PSA solution. These results show that all PSA is present at the 
IL-rich phase (no peak is detected at the salt-rich phase), meaning the studied system 
allows to completely extract and concentrate PSA in the IL-rich in a single-step. The CF of 
250-fold allows to identify and quantify PSA by SE-HPLC with a DAD detector. 
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Figure 2.4- HPLC chromatogram of standard PSA aqueous solution (at 150 ng.mL-1), and top (IL-rich phase) 
and bottom (salt-rich phase) phases of the system formed by [P4444]Cl + C6H5K3O7 + aqueous solution of 
PSA at 150 ng.mL-1 .   
In summary, the obtained data show the possibility to extract and concentrate PSA 
up to 250-fold, in a single-step, using IL-based ABS. These findings highlight the 
possibility to apply these IL-based ABS to the early-stage diagnosis of prostate cancer. The 
studied ABS represents an additional advantage in PSA extraction and quantification, since 
it leads 100% of extraction efficiency with a reduced amount of IL used. Although the 
extraction of other proteins from human fluids with IL-based has been previously reported 
(134), extractions of 100% were not attained in single-step nor concentration factors up to 
250-fold. The use of phosphonium-based ILs has proven to lead to promising results. 
According to these results, the extraction of PSA from real human fluids using the same 
and optimized system was further studied. 
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2.3.2 Extraction and concentration of PSA from human urine  
The ABS composed of [P4444]Cl + C6H5K3O7 + water allows to concentrate an 
aqueous solution of PSA at 150 ng.mL-1 up to 250-fold, as demonstrated in the previous 
section. Therefore, the same mixture composition was used with human urine samples 
instead of using an aqueous solution synthetically prepared with PSA. Nevertheless, it 
should be remarked that urine samples of healthy patients were used and these samples 
were spiked with pure PSA at concentrations of 150 ng.mL-1 (Figure 2.5).  
 
IL-rich phase
Salt-rich phase
 
Figure 2.5- ABS composed of [P4444]Cl + C6H5K3O7 + human urine (with added PSA at 150 
ng.mL-1). 
 
After the ABS equilibration, the top and bottom phases were separated and analysed 
by SE-HPLC, as well as a solution of pure PSA in PBS buffer and pure human urine 
samples. Results obtained are shown in Figure 2.6 and correspond to an aqueous solution 
containing standard PSA, to the urine sample with no pre-treatment, and to the top and 
bottom phases of the ABS for the synthetic system and for the extraction with real human 
urine samples. 
  The PSA peak in aqueous solution is evident between 12 and 15 min, being also 
seen in the top phase of the [P4444]Cl-based ABS for both the synthetic and human urine 
samples. This peak is absent in the bottom phase of the same ABS, proving that all PSA 
migrates to the IL-rich phase, in single-step, even in the presence of a complex matrix such 
as urine. In addition, no metabolites or proteins are detected in the urine sample without 
pre-treatment. However, additional peaks are observed in the IL-rich phase after the 
extraction carried out from human urine. It is known that 2500 metabolites are present in 
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human urine (158), although at this stage it is not possible to identify them. Further studies 
by Mass Spectrometry are required to gather evidences on the major metabolites being 
simultaneously extracted to the IL-rich phase. Even so, the presence of these metabolites 
does not interfere with the identification and quantification of PSA in human urine samples 
after the pre-treatment strategy, meaning that IL-based ABS are remarkable systems to 
simultaneously extract and concentrate PSA from human fluids further allowing the 
quantification of PSA by SE-HPLC. 
PSA aqueous solution
IL-rich phase
Salt-rich phase
Salt-rich phase (PSA aqueous solution
IL-rich phase (PSA aqueous solution
Urine sample
Salt-rich phase ( with urine)
IL-rich phase ( with urine)
 
Figure 2.6 - HPLC profile of a standard PSA aqueous solution (at 150 ng.mL-1), a human urine 
sample, and top and bottom phases of the IL-based ABS after the extraction with PSA in aqueous solution 
and with human urine (PSA at 150 ng.mL-1). 
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2.4 Conclusions  
The ability of IL-based ABS to completely extract and concentrate PSA up to 250-
fold, in a single-step, from human urine samples, has been demonstrated. This achievement 
allows the identification and quantification of PSA by more expedite equipment, like 
HPLC with a DAD detector. Based on these results, human samples used for PCa early 
diagnosis can be pre-treated with IL-based ABS before proceeding for analytical 
quantification. Although other metabolites present in urine samples were also identified at 
the IL-rich phase, they do not interfere with the quantification of the target biomarker. 
Nevertheless, additional studies are required to identify the main metabolites present and 
being extracted to the IL-rich phase.  
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3.1  Introduction 
Serum is a source rich in several biochemical products that can act as biomarkers of 
diseases or of the physiological status of a patient (159). It is estimated that there are 
10,000 different proteins in human serum, the majority of which are low-molecular-weight 
species (160). Albumin is the main protein found in mammals serum, being an anionic 
protein, with a large abundance of aspartate and glutamate residues; among all serum 
proteins, it has a molecular weight of 67 kDa and a longer-than-average half-life of 
approximately 20 days (161). Albumin is required to maintain the osmotic balance 
between intravascular and interstitial spaces; therefore, a deficiency in albumin ordinarily 
results in edema as water is redistributed to tissues. Albumin also functions as a transport 
protein for calcium, unconjugated bilirubin, thyroid hormones, and many drugs (161).  
 When particularly dealing with serum samples, the removal of interference 
proteins is an essential step in samples preparation for analysis (162). Protein precipitation 
followed by centrifugation is one of the most popular techniques for removing proteins 
(163). Proteins are usually less soluble when at their isoelectric point (pI); therefore, the 
selection of aqueous solutions of salt at pH values near the pI of the target protein is 
usually appropriate for their precipitation (163). However, developing a selective 
precipitation technique for a particular protein requires the identification of the appropriate 
precipitating agent and optimization of the precipitation procedure (164). Some reagents 
cause denaturation or adversely affect proteins bioactivity, and some form complexes that 
bind the protein tightly. Other methods lack the ability to selectively fractionate and enrich 
the desired protein (165). Moreover, the precipitation of proteins is a method not well-
suited for high throughput analysis due to the multiple steps involved given the large 
number of proteins present in serum samples.  
 Proteins present in serum and plasma span a concentration range of 11 orders of 
magnitude, with the 20 most abundant proteins representing 97–99% of the total protein 
mass content (166). Hitherto, no single analytical method is capable of resolving all plasma 
or serum proteins, and no detection method can cover more than 4 or 5 orders of 
magnitude (167). Due to limitations in resolution, and because of the high abundance of a 
relatively small number of proteins, most analytical schemes for serum and plasma involve 
the depletion of high-abundance proteins to reduce both the complexity and dynamic range 
of the samples. On the other hand, for both laboratory and larger scales protein 
fractionation of biological samples, there is a crucial need to remove cellular proteins and 
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other components (168). It is especially important to remove proteases, as early as 
possible, to avoid the remaining proteins degradation. 
 Regarding the follow-up of patients with prostate cancer, lactate dehydrogenase 
(LDH) has been playing a pivotal role as a valuable biomarker (96). It is usually identified 
in serum samples (168). In serum, LDH is involved in the catalysis of the conversion of 
lactate into pyruvate. Due to its widespread localization in human tissues, the activity of 
this enzyme also considerably increases in blood after cell damage, which can be attributed 
to a large number of pathological conditions, including cardiac and liver injury, 
haematological disturbances, and cancer (169).  
Several methods have been developed for the measurement of total LDH activity, 
categorized as either spectrophotometric or calorimetric (170). The bidirectional reaction is 
usually monitored spectrophotometrically by measuring either the increase in reduced 
NADH at 340 nm produced in the lactate-to-pyruvate reaction or by the decrease in NADH 
at 340 nm produced in the pyruvate-to-lactate reaction (168) Currently, LDH is quantified 
by kinetic assay systems by following the reversible reaction in both directions. The 
pyruvate kinase–lactate dehydrogenase coupled enzyme system has been successfully 
applied to the spectrophotometric determination of LDH activity (171). Although 
spectrophotometric assays are easy to perform and robust, they have some limitations. The 
reading must occur in the first seconds of reaction after adding serum samples, since most 
of the times all NADH is consumed even before the first reading (169). Furthermore, 
interferences display a significant role over the kinase activity when dealing with crude 
preparations or extracts (172). 
              Based on the exposed above, there is an essential need to develop alternative pre-
treatment strategies to avoid interferences of main proteins present in plasma samples 
when the identification and quantification of biomarkers is required for diagnosis. Instead 
of quantifying the enzymatic activity of LDH, the quantification of the enzyme effective 
concentration could be seen as a more reliable approach.  
 In this section, the main goal consists on the development of pre-treatment 
methods of serum samples so that cancer biomarkers, such as LDH, could be extracted and 
major contaminant proteins removed at the same time. This strategy allows the reduction 
of interferences during the quantification of cancer biomarkers for diagnosis. To this end, 
IL-based ABS were investigated as a possible alternative to extract and purify LDH from 
serum samples. The major goal is to find an ABS able to completely extract LDH for the 
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IL-rich phase and that allows the simultaneous precipitation/removal of HSA. As a first 
attempt, synthetic samples where used and the best systems were finally applied to human 
serum samples. 
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3.2  Experimental Section 
 
3.2.1  Chemicals   
In this section, ABS formed by the potassium citrate buffer at pH = 7, composed of 
potassium citrate C6H5K3O7∙ H2O> 99 wt% pure, from Sigma-Aldrich, and citric acid 
C6H8O7, 100 wt% pure, from Misher scientific, in a ratio 25:1, were investigated. Two ILs 
were studied to form ABS with the citrate buffer, namely tetrabutylphosphonium bromide 
([P4444]Br), > 96 % pure, and tetrabutylphosphonium chloride ([P4444]Cl), > 96 % pure, 
both from Cytec Ind.. The chemical structures of the ILs studied are represented in Figure 
3.1. For HPLC analysis, sodium phosphate monobasic (NaH2PO4, purity: 99- 100.5%), 
sodium phosphate dibasic (Na2HPO4
.7H2O, purity 98.2- 102.0 %) and sodium chloride 
(NaCl, purity 99.9%) were used to prepare a phosphate buffer solution at pH=7. For LDH 
analysis, an aqueous solution of Lactate Dehydrogenase from bovine heart (1000 U.L-1), 
from Sigma-Aldrich, was employed. LDH dilutions were prepared with aqueous solutions 
of phosphate buffered saline (PBS), 100 wt% pure, from Sigma-Aldrich. 
 
 
Figure 3.1- Chemical structure of the studied ILs: [P4444]Br and [P4444]Cl. 
 
 
3.2.2  Biological samples 
Sterile-filtered serum human samples from male individuals, AB type of plasma, 
from Sigma-Aldrich were used. 
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3.2.3  Phase diagrams, tie-lines and LDH extraction and 
purification with IL-based ABS 
          The binodal curves required to infer on the mixture compositions needed to form 
two-phase systems were taken from the literature (136), determined thought the cloud 
point titration method at 25 (±1) ºC and atmospheric pressure (Appendix A). The 
experimental procedure adopted was described before in section 2.2.3. 
Tie-lines were determined by the gravimetric method and using the lever-arm rule 
originally proposed by Merchuk et al (154). For this purpose, a selected mixture at the 
biphasic region was chosen and prepared by weighting the appropriate amounts of IL+ salt 
+ water, followed by stirring. Similar experimental conditions were adopted to the ones 
described in section 2.2.3. The experimental binodal curves were fitted by equation 1, the 
TLs determined by equations (2-5), and the TLL determined through the application of 
equation (6), previously described in section 2.2.3.  
  For the partitioning experiments, it was chosen a specific ternary mixture 
composition based on the phase diagrams used in this section, namely 30 wt% IL+ 30 wt% 
salt+ 40 wt% of LDH aqueous solution/serum for both IL-based systems, all systems were 
performed for a final weight of 1 g. The LDH aqueous solution used was prepared by 
dilution of the same in PBS aqueous solution to achieve a final concentration of 100 U.L-1, 
used to prepare the synthetic samples. For systems with human serum, serum sample was 
used by addition to the system in its pure state. Each mixture was vigorously stirred, 
centrifuged for 10 min at 3500 rpm and at 25 (± 1) ° C, to reach the complete partitioning 
of the enzyme between the coexisting phases.  
After a careful separation of the phases, the amount of LDH in each phase was 
quantified by SE-HPLC according the procedure described in section 2.2.4. The calibration 
curve for LDH is represented in Appendix C. The limit of detection of LDH was found to 
be 25 U.L-1. The salt and IL interferences with the method of quantification were also 
verified and control samples were regularly analysed.  
The percentage extraction efficiency of the studied systems for LDH, EELDH%, is 
the percentage ratio between the amount of protein in the IL-rich aqueous phase to that in 
the total mixture, and is defined according to equation 9: 
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𝐸𝐸𝐿𝐷𝐻% =  
[𝐿𝐷𝐻]𝐼𝑙 × 𝑤𝐼𝐿
[𝐿𝐷𝐻]𝐼𝑙 × 𝑤𝐼𝐿 + [𝐿𝐷𝐻]𝑆𝑎𝑙𝑡 × 𝑤𝑆𝑎𝑙𝑡
 × 100 
                           (9) 
where [LDH] is the LDH concentration, and wIL and wsalt are the total weight of the 
protein in the IL-rich and in the salt-rich aqueous phase, respectively.   
The percentage extraction efficiency of serum proteins, EESerumProteins%, is the 
percentage ratio between the amount of protein in the IL-rich aqueous phase to that in the 
total mixture, and is defined according to equation 10: 
 
𝐸𝐸𝑆𝑒𝑟𝑢𝑚𝑃𝑟𝑜𝑡𝑒𝑖𝑛𝑠 % =  
[𝑆𝑒𝑟𝑢𝑚𝑃𝑟𝑜𝑡𝑒𝑖𝑛𝑠]𝐼𝑙 × 𝑤𝐼𝐿
[𝑆𝑒𝑟𝑢𝑚𝑃𝑟𝑜𝑡𝑒𝑖𝑛𝑠]𝐼𝑙 × 𝑤𝐼𝐿 + [𝑆𝑒𝑟𝑢𝑚𝑃𝑟𝑜𝑡𝑒𝑖𝑛𝑠]𝑆𝑎𝑙𝑡 × 𝑤𝑆𝑎𝑙𝑡
 × 100 
 (10) 
where [SerumProteins] is the serum proteins concentration, and wIL and wsalt are the 
total weight of the protein in the IL-rich and in the salt-rich aqueous phase, 
respectively.   
The percentage of precipitation efficiency of LDH, PELDH%, was evaluated basing 
in the amount of LDH detected in IL-rich phase and salt-rich phases, since no LDH was 
quantified in both phases, all LDH was admitted to be present in the third phase, being 
result of the percentage ratio between the amount of protein in the third phase and the 
amount present in the total mixture. 
            
𝑃𝐸𝐿𝐷𝐻% =  
[𝐿𝐷𝐻]3𝑟𝑑𝑃ℎ𝑎𝑠𝑒
[𝐿𝐷𝐻]𝑡𝑜𝑡𝑎𝑙
 × 100 
               (11) 
where [LDH] is the concentration of LDH. 
The percentage of precipitation efficiency of serum proteins, PESerumProteins%, was 
evaluated basing in the amount of serum proteins detected in IL-rich phase and salt-rich 
phases, since no serum proteins were quantified in both phases, all serum proteins were 
admitted to be present in the third phase, being result of the percentage ratio between the 
amount of protein in the third phase and the amount present in the total mixture. 
     
𝑃𝐸𝑆𝑒𝑟𝑢𝑚𝑃𝑟𝑜𝑡𝑒𝑖𝑛𝑠 % =  
[𝑆𝑒𝑟𝑢𝑚𝑃𝑟𝑜𝑡𝑒𝑖𝑛𝑠]3𝑟𝑑𝑃ℎ𝑎𝑠𝑒
[𝑆𝑒𝑟𝑢𝑚𝑃𝑟𝑜𝑡𝑒𝑖𝑛𝑠]𝑡𝑜𝑡𝑎𝑙
 × 100 
                            (12) 
where [SerumProtein] is the concentration of serum proteins. 
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3.2.4 Extraction and purification of LDH from serum samples 
 After extractions with both IL-based ABS in the point of mixture refered 
in previous section was possible to select the best IL-based ABS to use in real sample 
treatment. From the [P4444]Br-based phase diagram and respective tie-lines determined in 
the previous section, it was possible to select several mixture points in the biphasic region, 
by varying the IL and salt percentages. Several initial mixture compositions formed by 30 
wt% IL+ 15, 20 and 30 wt% salt + respective wt% of LDH solution and serum were tested, 
and for the variation of IL, the points of mixture 20, 30 and 45 wt% IL+ 30 wt% salt + 
respective wt% of LDH solution and serum were evaluated. The LDH aqueous solution 
used was prepared by dilution of the same in PBS aqueous solution to achieve a final 
concentration of 100 U.L-1, used to prepare the synthetic samples. For systems with human 
serum, serum sample was used by addition to the system in its pure state. After 
optimization, the best point of mixture was selected for the extraction of LDH and 
precipitation of serum protein from serum samples. The extraction and purification of LDH 
in real samples was performed by the dilution of 1:10 of initial LDH solution directly in 
the serum sample to reach a concentration of 100 U.L-1.  
 Each mixture prepared was vigorously stirred, centrifuged for 10 min at 3500 
rpm and at 25 (± 1) ° C. After the separation of the phases, the amount of LDH in each 
phase was quantified by SE-HPLC by the procedure described in section 2.2.4. The 
presence of serum contaminants proteins was also confirmed. The salt and IL interferences 
with the analytical method were also verified and control samples were regularly analysed. 
 
3.2.5. Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) 
Human serum proteins present in third phase of the IL-based ABS were 
analysed by SDS-PAGE. The serum proteins were diluted 2:1 (v:v) in PBS buffer 
before its aplication in SDS-PAGE method thanks to the high protein content of the 
sample.  Samples of the aqueous phases of each ABS containing ovalbumin were diluted 
at 2:1 (v:v) in a dissociation buffer consisting of 2.5 mL of 0.5 M Tris-HCl pH 6.8, 4.0 mL 
of 10 % (w/v) SDS solution, 2.0 mL of glycerol, 2.0 mg of bromophenol blue and 310 mg 
of dithiothreitol (DTT). This overall solution was heated at 95ºC for 5 min to denature the 
proteins by reducing disulfide linkages, and thus overcoming some forms of the tertiary 
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protein folding and breaking up the quaternary protein structure. Electrophoresis was run 
on polyacrylamide gels (stacking: 4 % and resolving: 20 %) with a running buffer 
constituted by 250 mM Tris-HCl, 1.92 M glycine, and 1 % SDS. The proteins were stained 
with Coomassie Brilliant Blue G- 250 0.1 % (w/v), methanol 50 % (v/v), acetic acid 7 % 
(v/v) and water 42.9 % (v/v). All gels were placed in an orbital shaker at a moderate speed 
during 2-3 h at room temperature. The gels were further distained in a solution containing 
acetic acid at 7 % (v/v), methanol at 20 % (v/v) and water at 73 % (v/v) in an orbital shaker 
at a moderate speed during 3-4 h at room temperature. SDS-PAGE Molecular Weight 
Standards, namely marker molecular weight full-range from VWR, were used as protein 
standards. 
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3.3  Results and discussion 
3.3.1 Phase diagrams, tie-lines and extraction of LDH using IL-
based ABS 
            The phase diagrams for the systems consisting of IL + H2O + C6H5 K3O7/C6H8O7 
(pH = 7.0) were determined at 25 ◦C and atmospheric pressure (136) and are depicted in in 
Appendix A. All the calculations considering the weight fraction of the phase-forming 
components were carried out discounting the complexed water in the commercial citrate-
based salt. The phase diagrams reported before (136) for the systems constituted by 
phosphonium-based ILs allow the evaluation of both ILs ability to form ABS, following 
the order [P4444]Br > [P4444]Cl. This is in close agreement with the trend previously 
described in the literature for ABS composed of phosphonium-based ILs +K3PO4 + H2O 
(144). The Cl- anion presents a higher aptitude to be hydrated or to form hydration 
complexes, and thus more salt is required to induce the salting-out when compared with 
bromide-based ILs (168).  
             The experimental data corresponding to the binodal curves were fitted using 
equation (1) and this correlation is shown Appendix A. The regression parameters 
estimated by least-squares regression, standard deviations (σ) and correlation coefficients 
(R2) are displayed in Appendix A. The experimental TLs in each ABS, along with their 
respective length, and at the compositions for which the extraction studies were conducted 
are reported in Table 3.1. These allow to identify the content of each component in the 
coexisting phases for each initial mixture composition. The tie-lines obtained for both 
systems are depicted in Figure. 3.2.  
Table 3.1 - Weight fraction percentage (wt%) for the coexisting phases of ionic liquid (IL)+ potassium 
citrate (salt) + H2O, and respective values of TLL. 
Weight fraction composition/ (wt%)  
IL + C6H5K3O7/C6H8O7 + H2O 
IL YT % XT % YM% XM% YB % XB % TLL 
[P4444]Cl 
80.98      0.83      28.82 29.10 0.56 44.43 91.48 
75.06 1.20 27.08 27.09 1.08 41.11 84.05 
[P4444]Br 58.75 0.05 29.17 29.38 0.02 58.30 82.72 
 52.02 0.21 19.99 20.30 1.74 31.75 59.35 
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Figure 3.2-  Phase diagrams at 25 ◦C and atmospheric pressure (2), correlation of the binodal data using 
equation (1), and respective TLs for the systems composed of C6H5 K3O7/C6H8O7 + H2O + [P4444]Br (●); 
[P4444]Cl (■). 
The extraction efficiencies of LDH and serum proteins with the studied IL-based 
ABS were initially addressed for a mixture composition of 30 wt% of C6H5 K3O7/C6H8O7, 
30 wt% IL and 40 wt% of an aqueous solution containing either LDH at 100 U.L-1 or 
human serum, and calculated according equations (9) and (10) and efficiency of extraction 
accordinh equations (11) and (12). Both aqueous solutions were tested using both ILs: 
[P4444]Cl and [P4444]Br. The results obtained are depicted in Figure 3.3. 
In this mixture composition, it is possible to verify that both types of IL-based ABS 
lead to the complete extraction of LDH to the IL-rich phase, with extraction efficiencies of 
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100% attained in a single-step and with no precipitation of this protein in both systems 
studied.  
However, in the serum protein extraction, it was possible to verify that although the 
system C6H5K3O7/C6H8O7 + [P4444]Cl is able to extract completely not only LDH but also 
serum proteins with extraction efficiencies of 100% attained in a single-step, the [P4444]Br-
based ABS, does not extract serum proteins for IL-rich phase, contrarily it leads to the 
complete precipitation of major serum proteins (also macroscopically visible, precipitates 
at the interface).  
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Figure 3.3- Extraction efficiency (EE%) and precipitation efficiency (PE%) for LDH () and  
serum proteins () at 25ºC and pH 7.0 in the ABS composed of IL+ C6H5K3O7/C6H8O7 + aqueous solution, 
using both ILs studied [P4444]Cl (A) and [P4444]Br (B). 
Concordant results were obtained by HPLC analysis of LDH aqueous solution and 
serum sample after the pre-treatment with IL-based ABS (Appendix D). The extraction of 
LDH from a standard aqueous solution displays a peak between 15 and 17 minutes in the 
HPLC chromatogram, corresponding to LDH, and is seen in both  top phases of the 
[P4444]Cl-based and [P4444]Br-based ABS. The extraction efficiency of 100% of both 
systems is further confirmed by the absence of the same peak in the chromatograms 
corresponding to the bottom phases. For extractions carried out from serum samples, in 
[P4444]Cl-based ABS an evident peak between the 17 and 18 minutes is verified. The 
bottom phase of this ABS presents no visible peaks, confirming that the extraction occurs 
with 100% efficiency. In serum extraction with [P4444]Br-based ABS, no peaks are 
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observed in the HPLC chromatogram, confirming that serum proteins are precipitated with 
100% efficiency. 
This behaviour of precipitation was recently reported by Pereira et al. (136), who 
demonstrated that [P4444]Br-based ABS induces the complete precipitation of bovine serum 
albumin (BSA).  In this work (136), a large variety of ABS were able to completely extract 
BSA for the IL-rich phase – with extraction efficiencies of 100%, with the exception of 
[P4444]Br. This IL, as the most hydrophobic IL investigated, led to the complete 
precipitation and/or denaturation of BSA. The data presented in this previous work (136) 
and in the present work indicate that changes in the protein structure may result from 
specific interactions occurring between the protein and this particular IL. Hydrophobic 
interactions responsible for proteins precipitation have been also reported with polymers, 
organic solvents and salts (174,175). Protein stability and enzyme activity can be strongly 
influenced by the type of salts present in the aqueous solution (176). For instance, Dryer et 
al. (177) reported that a dehydrogenase is more stable in the presence of ILs with more 
hydrophilic or salting-out-inducing anions, like Cl-. Br- has a weaker ability to hydrogen-
bond with water and to form hydration complexes, since it is a weaker salting-out anion 
than Cl- according to the Hofmeister series (176), a feature that seems to be responsible for 
promoting the protein denaturation. Although [P4444]Br leads to the complete precipitation 
of serum proteins in a single-step, at the same time, it allows the complete extraction of 
LDH to the IL-rich phase and is capable to maintain the stability of the target biomarker. It 
is expected that different ions interact in different ways with different proteins, resulting in 
the precipitation of some proteins and enhancing the stability of others. Still, the 
understanding of the molecular-level mechanisms responsible for this phenomenon 
requires more detailed investigation.  
Given the ability of [P4444]Br-based ABS to extract with 100% efficiency LDH 
while precipitating completely the serum proteins, this system was selected for further 
studies in the biomarkers quantification in human serum, since it’s the most advantageous 
in serum sample treatment while maintaining the extraction efficiency.  
In order to optimize this IL-based ABS for serum sample treatment, reducing the 
amount of salt and IL required to form ABS is needed, while keeping their ability to 
completely extract LDH and to completely precipitate serum proteins, in a single-step. In 
this sense, a series of ABS containing variable concentrations of [P4444]Br (15-45 wt%) and 
salt (10–30 wt%) were then evaluated. The effect of the salt concentration through the 
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extraction efficiency of LDH and serum protein precipitation is shown in Figure 3.4. All 
compositions studied allow the complete extraction of LDH and complete precipitation of 
serum proteins, without observing the precipitation and/or denaturation of the target 
biomarker.  
In the extraction/precipitation of serum proteins from serum samples, the mixture 
composed of 30 wt% of IL and 10 wt% of salt presented a relatively small top-phase 
compared to the bottom phase, which did not allow to separate the interface compose of 
precipitated serum proteins; however, through the quantification of bottom and top phases 
for same mixture composition by HPLC, it was possible to infer that there was no serum 
proteins present, meaning that it was completely precipitated. However, this system is not 
suitable for further studies due its relatively small top-phase, which makes difficult LDH 
quantification. 
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Figure 3.4- Extraction efficiency of LDH (EELDH%) and precipitation efficiency of serum proteins 
(PESerumProteins%) for the ABS composed of [P4444]Br+C6H5K3O7/C6H8O7 from a model aqueous solution: 
LDH () and serum () for different points of mixture variating salt amount, at 25ºC and pH 7.0. 
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Once the variation of the salt amount has been reported to drive the migration of 
proteins to the top phase due to a decrease in the difference of the electrostatic potential 
between the coexisting phases (178). Basing in this observations, and once low salt 
concentrations have less interference in proteins stability (179), the salt percentage chosen 
for further extractions with real samples, was 20% of C6H5K3O7/C6H8O7. The effect of the 
IL concentration through the extraction and precipitation efficiency of the LDH and serum 
proteins for the studied systems was also investigated. The results obtained are presented in 
Figure 3.5.  
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Figure 3.5- Extraction efficiency of LDH (EELDH%) and precipitation efficiency of serum proteins 
(PESerumProteins%)  for the ABS composed of [P4444]Br and C6H5K3O7/C6H8O7 from a model aqueous solution: 
LDH () and serum () for different points of mixture variating IL amount, at 25ºC and pH 7.0. 
 
The initial mixture formed by 30 wt% of C6H5K3O7/C6H8O7, 15 wt% of IL and 
using directly a serum sample, presented relatively low volume top-phase, not allowing the 
possibility to separate serum proteins in the interface from top-phase. However, during the 
quantification by HPLC, no serum proteins were detected in both phases, meaning that 
serum proteins have undergone a precipitation effect.  
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It should be remarked that in this mixture points there are some losses of protein. 
The mass balance for LDH extractions reveal losses between -5.75-2.02% for the mixture 
compositions referred before. Although the mixture formed by 30 wt% of IL+ 30 wt% salt 
is the one which leads to a lower loss of protein while maintaining a good separation of the 
coexisting phases, the mixture corresponding to 45 wt% of IL + 20 wt% of salt has 
additional advantages, namely a larger volume of the top-phase (IL-rich where LDH is 
enriched) and a well-defined third phase corresponding to precipitation of serum proteins, 
displaying thus additional benefits when carrying out the quantification of both proteins.  
In summary, the system [P4444]Br + C6H5K3O7/C6H8O7 (pH=7) seems promising to 
the extraction of LDH to the IL-rich phase and simultaneous precipitation of serum 
proteins (eliminating thus the major contaminant protein) from serum samples. Even 
though, further studies are required to evaluate if there are other serum proteins, present in 
lower content, which are concomitantly precipitated in the process. The obtained data 
represent a step forward towards the quantification of serum biomarkers, like LDH, since 
the sample purification can be achieved in a single-step. However, the applicability of 
these systems in real serum samples is required to guarantee their widespread use in early-
stage PCa diagnosis. 
 
3.3.2 Extraction and purification of LDH from human serum 
Since the initial mixture formed by 45 wt% [P4444]Br + 20 wt% C6H5K3O7/C6H8O7 
allows the best extraction versus precipitation and a better phases’ separation for further 
analysis, according to the investigations carried out in the previous section, it was then 
applied to carry out the simultaneous extraction of LDH and precipitation of serum protein 
from serum samples. To this end, LDH was added to serum samples to reach a 
concentration of 100 U.L-1. After the ABS preparation with real serum samples, both 
phases were separated and analysed by SE-HPLC.  
 Figure 3.6 represents the macroscopic appearance of an extraction carried out with 
the optimized ABS from a human serum sample, with both ILs. It is visually evident the 
precipitation of serum proteins as a third phase with [P4444]Br-based ABS, a phenomenon 
not visible with [P4444]Cl-based ABS.  
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Figure 3.5 – Pre-treatment of serum samples spiked with LDH using ABS composed of [P4444]Br + 
C6H5K3O7/C6H8O7 (in the left) and of [P4444]Cl + C6H5K3O7/C6H8O7 (in the right), evidencing the presence 
and absence of a third phase corresponding to precipitated protein. 
 
The SE-HPLC chromatograms used for the LDH and serum proteins quantification 
in each phase confirm the presence of LDH, only at the IL-rich phase, as well as the 
absence of LDH aggregates or the protein fragmentation – Figure 3.6. The SE-HPLC 
chromatograms for standard solutions of both proteins as well as for a serum sample (with 
no pre-treatment) are also shown in Figure 3.6. From the protein profile in serum samples 
it is evident that the major contaminant protein is HSA. LDH is not detectable since the 
commercial serum samples used correspond to healthy volunteers. For this reason it should 
be remarked that before the ABS pre-treatment step, serum samples were spiked with LDH 
to reach a final concentration of 100 U.L-1.  Less intense peaks are also visible in the 
HPLC profile of the human serum samples; however, further studies, are required to 
identify which proteins are present.  
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Figure 3.6- SE-HPLC chromatogram of standard LDH and HSA aqueous solutions, serum sample 
(dilution 1:10 in PBS solution) without pre-treatment, and top and bottom phases of the ABS composed of 
[P4444]Br + C6H5K3O7/C6H8O7 with serum samples. 
 
The peak of LDH in aqueous solution at concentration of 100 U.L-1 has a retention 
time of 16.48 minutes in the HPLC chromatogram. This peak is also evident in the HPLC 
profile of the IL-rich phase and is absent in the salt-rich phase.  In summary, and from the 
results obtained, it is clear that IL-based ABS allow the complete extraction of LDH to the 
IL-rich phase in a single-step, and at the same time allow the removal of at least two 
proteins from serum samples which act as major contaminants (retention times of 15.88 
and 17.26 min), acting simultaneously as extraction and purification platforms. Since 
human serum presents at least 375 distinct proteins, and albumin is in major content in 
serum samples, is possible to infer that the major contaminant with the highest peak, must 
correspond to this specific protein (180). Basing in HSA retention time, of 17.26 minutes, 
is possible to conclude that this protein has the same retention time that one of the major 
contaminants found in serum sample chromatogram. Therefore, the IL-based ABS allows 
the complete removal of the HSA from the IL-rich and salt-rich phase. However, other 
proteins of high concentration can be precipitated as well, having similar retention times. 
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To evaluate which proteins are precipitating in third phase, SDS-PAGE was performed, 
and the respective results are depicted in Fig. 3.7. 
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Figure 3.7-SDS-PAGE analysis of serum proteins in third phase of IL-based ABS. (a) Molecular weight 
marker; (b) HSA sample, 1g.L-1; (c) human serum proteins precipitated in third phase of the IL-based ABS 
(diluted 2:1 in PBS buffer). 
 According to literature, SDS-PAGE presents approximately 3700 distinct protein 
spots for human serum proteins, basing in the observation of Figure 3.7, not only HSA is 
precipitated in the third phase, but proteins of high concentration in serum like, IgG, 
antitrypsin, transferrin, haptoglobin, fibrinogen, alpha2-macroglobulin, may be precipitated 
as well (180,181). Which is in accordance with the results obtained, once these proteins 
appear in SDS-PAGE gel spots from 150kDa to 17 kDa. 
  The referred observations allows to conclude that the IL-based ABS studied 
represents an effective pre-treatment method for complex samples such human serum, 
being able to remove the high protein content that interferes in cancer biomarkers 
quantification, like LDH. 
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3.4 Conclusions  
Taking into account the previous results, it is possible to conclude that IL-based 
ABS have a remarkable potential to be applied as pre-treatment strategies of human fluids 
in cancer diagnosis. Optimized ABS allow the simultaneous extraction of the target 
biomarker (LDH) and the precipitation of the most abundant protein in human plasma 
(HSA). This pre-treatment approach allows the analysis of serum samples by HPLC, and 
making use of its effective concentration instead of enzymatic activity. This fact is 
particularly relevant since effects of solvents on enzymatic activity and respective 
interferences are completely eliminated. At this stage, the validation of the proposed pre-
treatment method needs to be more deeply evaluated by their application with a wide 
number of samples, and the correct identification of all precipitated proteins and those at 
the IL-rich phase need to be pursued. 
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4. Final remarks and future work  
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IL-based ABS were here proposed as pre-treatment methods of human fluids for the 
extraction, concentration and purification of cancer biomarkers. IL-based ABS allow the 
complete extraction and concentration of PSA up to 250-fold, a single-step, to the IL-rich 
phase. This remarkable achievement allows the identification and quantification of PSA in 
human urine samples at cut-off values indicative of prostate cancer. Nevertheless, it is still 
needed to characterize and identify the remaining urine metabolites also present in the IL-
rich phase. IL-based ABS also allowed the complete extraction and purification of LDH 
from human serum, a single-step. In this particular case, optimized IL-based ABS allow 
the complete extraction of the target biomarker and the simultaneous and complete 
precipitation of the major contaminant protein present in serum, which leads to a purified 
sample for further analysis. However, and as stated before with the PSA samples, also in 
this type of studies it is still required to identify the remaining contaminant proteins which 
are precipitating along with HSA.  
The results presented in this work reinforce the opportunity of using IL-based ABS 
as pre-treatment strategies of human fluids for a more reliable and accurate PCa diagnosis. 
The developed pre-treatment methods allow the identification and quantification of PSA 
and LDH in human fluids by more expedite equipment, such as HPLC. The future routine 
use of HPLC for biomarkers quantification, instead of the currently applied immunoassays, 
will provide more reliable result while avoiding the high current number of false positive 
and negative results. Nevertheless, much more work is required on this direction to 
implement the combined pre-treatment-quantification approach in clinical laboratories. A 
widespread and deep validation of the technology still needs to be conducted by applying 
them in the treatment and analysis of a significant number of human fluids from PCa 
patients. It should be highlighted that samples from a group of healthy individuals and 
prostate cancer volunteers are being currently collected, and that we continue to work on 
this subject in the near future. In a first approach, ABS capable of extracting LDH and 
precipitating human albumin (as the major contaminant) from serum in a single step will 
be investigated. As a second approach, ABS for the extraction and concentration of PSA 
from urine samples will be studied. Both biomarkers will be identified and quantified by 
HPLC-DAD, and both approaches will be applied to real samples collected from 50 control 
and 50 prostate cancer volunteers (40-85 years-old men) from Centro Hospitalar Cova da 
Beira, Covilhã, Portugal. The samples already started to be collected and are being 
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preserved at -80ºC. The samples collection was approved by the University of Beira 
Interior, Faculty of Health Sciences Ethics Committee (CE-FCS-2015-021). 
 
 
 
 
 
 
 
 
 
 
 
 67 
 
 
 
 
 
 
 
 
 
 
 
 
5.  REFERENCES 
 
 68 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 69 
 
1.  Exploring cancer proliferative signaling pathways. (2015) Scientific T. Accessed on 
September 29, 2015; Available from: 
http://www.thermofisher.com/content/dam/LifeTech/global/promotions/global/images/aai-
2015/aai pdfs/CancerProliferativePathwaysHandbook-r2.pdf. 
2.  World Health Organization. (2012) Prostate Cancer Estimated Incidence, Mortality and 
Prevalence Worldwide in 2012. Accessed on September 29, 2015; Available from: 
http://globocan.iarc.fr/pages/fact_sheets_cancer.aspx. 
3.  Henry, N. L., Hayes, D. F. (2012) Cancer biomarkers. Molecular Oncology; 6(2):140–6.  
4.  Thomas, C. M. G, Schmitt, M., Sweep, F. (2006) Analytical Aspects of Biomarker 
Immunoassays in Cancer Research; 17–31.  
5.  Longo, G. (2014) Detected twice for good measure A DNA that conducts. Nature 
Publishing Group; 9(12):959–60.  
6.  World Health Organization (2015) Cancer. Accessed on October 3, 2015; Available from: 
www.who.int/mediacentre/factsheets/fs297/en/.  
7.  World Cancer Research Fund International (2012) Worldwide data. Accessed on October 
3, 2015; Available from: www.wcrf.org/int/cancer-facts-figures/worldwide-data.  
8.  World Cancer Research Fund International (2012) Data for cancer frequency by cancer. 
Accessed on October 3, 2015; Available from: www.wcrf.org/int/cancer-facts-figures/data-
cancer-frequency-country.  
9.  Jemal, A., Bray, F., Ferlay, J. (2011) Global Cancer Statistics: 2011. CA: A Cancer Journal 
for Clinicians; 61:1:69–90.   
10.  International Agency for Research on Cancer. World Health Organization (2012) Acessed 
on October 4, 2015; Available from: 
http://eco.iarc.fr/eucan/Country.aspx?ISOCountryCd=620.  
11.  Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C., Parkin, D. M. (2010) Estimates of 
worldwide burden of cancer in 2008: Globalcan 2008. International Journal of Cancer; 
127, 2893–2917. 
12.  Kumar, V., Abbas, A., Aster J. (2013) Robbins Basic Pathology. Elsevier Saunders; 9th 
edition.  
13.  Yates L. R., Campbell P. J. (2013) Evolution of the cancer genome. Nature Reviews 
Genetics; 13 (11):795–806.  
14.  Pepper, J. W., Findlay, C. S., Kassen, R., Spencer S. L., Maley C. C. (2009) Cancer 
research meets evolutionary biology. Evolutionary Applications; 2(1):62–70 
 70 
 
15.  Hanahan, D., Weinberg, R. A. (2011) Hallmarks of cancer: the next generation. Cell. 
Elsevier Inc.; 144(5):646–74.   
16.  Hanahan, D., Weinberg, R. A., Francisco, S. (2000) The Hallmarks of Cancer. Cell. 
Elsevier Inc.; 100:57–70.  
17.  Lane, D. P. (1992) Cancer. p53, guardian of the genome. Nature. 358:15–16.  
18.  Wu, H., Chang, D., Huang, C. (2006) Targeted-therapy for cancer. Journal of cancer 
molecules; 2(2):57–66.  
19.  Sirica, A. (1989) The pathobiology of neoplasia. Plenum Press; 1:25–38.  
20.  Baba, A. I., Câtoi, C. Comparative Oncology. Academic Press. 2007. 
21.  Luo, J., Duggan, D.J., Chen, Y., Sauvageot, J., Ewing, C.M., Bittner, M.L., Trent, J. M., 
Isaacs, W. B., (2001) Human prostate cancer and benign prostatic hyperplasia: Molecular 
dissection by gene expression profiling. Cancer Research; 61(12): 4683–4688.  
22.  Ziada, A., Rosenblum, M., Crawford, E. D. (1999) Benign prostatic hyperplasia: an 
overview. Urology; 53(3):1–6.  
23.  Spickett, I., Robertson, J. (2010) Prostate cancer: the ongoing challenge. Men’s Health; 20.  
24.  Dunn, M. W. and Kazer, M.W.  (2011) Prostate cancer review. Semin Oncology Nurs; 
27(4):241–50.  
25.  Damber, J., Aus, G. (2008) Prostate cancer. The Lancet; 371:1710-1721. 
26.  Bostwick, D. G., Burke H. B., Djakiew, D., Euling, S., Ho S., Landolph, J., Morrison, H., 
Sonawane, B., Shifflett, T., Waters, D. J., Timms, B. (2004) Human prostate cancer risk 
factors. Cancer, 2371–490.  
27.  Loeb, S., Schaeffer, E. M. (2009) Risk Factors, Prevention and Early Detection of Prostate 
Cancer. Prim Care; 36:603–621.  
28.  Turner, B. Drudge-Coates L. (2010) Prostate cancer: risk factors, diagnosis and 
management. Cancer nursing practice; 9(10):29–35.  
29.  Bhavsar, A., Verma, S. (2014) Anatomic Imaging of the Prostate. BioMed Research 
International; 2014.  
30.  Srigley, J. R. (2004) Benign mimickers of prostatic adenocarcinoma. Modern pathology; 
17:328–48.  
31.  Coffey, D. S., James P., Karr R. G., Molecular and Cellular Biology of Prostate Cancer. 
Springer Sci. 2012;  
32.  Sadikovic, B, Squire, J. A, Zielenska M. (2008) Cause and Consequences of Genetic and 
Epigenetic Alterations in Human Cancer. Current Genomics; 9:394–408.  
 71 
 
33.  Singh, D., Febbo, P. G., Ross, K., Jackson. D. G., Manola, J., Ladd, C., Tamayo, P., 
Renshaw, A. A., D'Amico, A. V., Richie, J. P., Lander, E. S., Loda, M., Kantoff, P. W., 
Golub, T. R., Sellers, W. R. (2002) Gene expression correlates of clinical prostate cancer 
behavior. Cancer Cell; 1(2):203–9.  
34.  True, L., Coleman, I., Hawley, S., Huang, C., Gifford, D., Coleman, R., Beer, T. M., 
Gelmann, E., Datta, M., Mostaghel, E., Knudsen, B., Lange, P., Vessella, R., Lin, D., 
Hood, L., Nelson, P. S. (2006) A molecular correlate to the Gleason grading system for 
prostate adenocarcinoma. Proceedings of the National academy of Sciences; 
103(29):10991–6. 
35.  Meiers, I., Shanks, J. H., Bostwick D. G. (2007) Glutathione S-transferase pi (GSTP1) 
hypermethylation in prostate cancer: review 2007. Pathology; 39:299–304.  
36.  Bastian, P. J., Palapattu, G. S., Lin, X., Yegnasubramanian, S., Mangold, L. A., Trock, B., 
Eisenberger, M. A., Partin, A. W., Nelson, W. G. (2005) Preoperative serum DNA GSTP1 
CpG island hypermethylation and risk of early prostate-specific antigen recurrence 
following radical prostatectomy. Clinical cancer research; 11:4037–4043.  
37.  Cookson, M. S., Reuter, V. E., Linked, I., Fair, W. R. (1997) Glutathione Stransferase Pi 
(GST-pi) class expression by immunohistochemistry in benign and malignant prostate 
tissue. Journal of Urology; 157: 673–6.  
38.  Chang, B. L., Liu, W., Sun, J., Dimitrov, L., Li, T., Turner, A. R., Zheng, S. L., Isaacs, W. 
B., Xu, J. (2007) Integration of Somatic deletion analysis of prostate cancers and germline 
linkage analysis of prostate cancer families reveals two small consensus regions for 
prostate cancer genes at 8p. Cancer Research; 67(9):4098–103.  
39.  Hawksworth, D., Ravindranath, L., Chen, Y., Furusato, B., Sesterhenn, I. A., McLeod, D. 
G., Srivastava, S., Petrovics, G. (2010) Overexpression of C-MYC oncogene in prostate 
cancer predicts biochemical recurrence. Prostate cancer prostatic Dis Nat; 13(4):311–5.  
40.  Katsogiannou, M., Ziouziou, H., Karaki, S., Andrieu, C., Henry de Villeneuve, M., Rocchi, 
P. (2015) The hallmarks of castration-resistant prostate cancers. Cancer Treatment 
Reviews: 41(7):588–97.  
41.  Ward, J. B., Henderson, R. E. (1996) Identification of needs in biomarker research. 
Environ Health Perspect; 104:895–900.  
42.  National Cancer Institute at the National Institutes of Health (2012) Biomarkers. Accessed 
on November 1, 2015; Available from: 
http://www.cancer.gov/publications/dictionaries/cancer-terms?CdrID=45618.  
 72 
 
43.  Mayeux, R. (2004) Biomarkers: potential uses and limitations. NeuroRx;1(2):182–8.  
44.  Sawyers, C. L. (2008) The cancer biomarker problem. Nature; 452(7187):548–52.  
45.  Füzéry, A. K., Levin, J., Chan, M. M., Chan, D. W. (2013) Translation of proteomic 
biomarkers into FDA approved cancer diagnostics: issues and challenges. Clinical 
Proteomics; 10(1):13.  
46.  Madu, C. O., Lu, Y. (2010) Novel diagnostic biomarkers for prostate cancer. Journal of 
Cancer. (1):150–77.  
47.  Bishop, M. C., Hardy, J. G., Taylor, M. C., Lemberger, M. L., Wastleand, R. J. (1985) 
Bone Imaging and Serum Phosphatases in Prostatic Carcinoma. British Journal of Urology; 
317–24.  
48.  Bussemakers M. J. G., van Bokhoven, A., Verhaegh, G. W., Smit F. P., Karthaus,  H. F. 
M., Schalken, J. A., Debruyne, F. M. J., Ru, N.,  Isaacs, W. B. (1999) DD3: a new 
prostate-specific gene, highly overexpressed in prostate cancer. Cancer Research; 59 
(23):5975–9.  
49.  Sartori, D A., Chan, D. W. (2014) Biomarkers in prostate cancer: what’s new? Current 
Opinion Oncology;26(3):259–64.  
50.  Crawford, E. D., Ventii, K., Shore, N. D. (2014) New Biomarkers in Prostate Cancer. 
Oncology.   
51.  Hakama, M., Auvinen, A., Day, N., E, Miller, A. B. (2007) Sensitivity in cancer screening. 
Journal of Medical Screening; 14(4):174–7. 
52.  Wu, L., Qu, X. (2015) Cancer biomarker detection: recent achievements and challenges. 
Chemistry Society Review; 44(10):2963–97.  
53.  Alvarez, M. A. (2014) Prostate cancer biomarkers. Journal of clinical ultrasound; 9(1):95–
8.  
54.  Hernández, J., Thompson. I. M. (2004) Prostate-specific antigen: A review of the 
validation of the most commonly used cancer biomarker. Cancer.; 101(5):894–904.  
55.  Thorek, D. L. J., Evans M. J., Carlsson, S. V., Ulmert, D., Lilja, H. (2013) Prostate-specific 
kallikrein-related peptidases and their relation to prostate cancer biology and detection. 
Established relevance and emerging roles. Journal of Thrombosis and Haemostasis; 
110(3):484–92.  
56.  Lilja, H. (1985) A kallikrein-like serine protease in prostatic fluid cleaves the predominant 
seminal vesicle protein. Journal of Clinical Investigation.; 76(5):1899–903.  
 73 
 
57.  Lilja, H,. Oldbring, J., Rannevik, G., Laurell, C. B. (1987) Seminal vesicle-secreted 
proteins and their reactions during gelation and liquefaction of human semen. Journal of 
Clinical Investigation; 80(2):281–5.  
58.  Cohen, P., Graves, H. C., Peehl, D. M., Kamarei, M., Giudice, L. Rosenfeld, R. G. (1992) 
Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease 
found in seminal plasma. Journal of Clinical Endocrinology & Metabolism; 75:1046–53.  
59.  Ménez, R., Michel, S., Muller, B. H., Bossus, M., Ducancel, F., Jolivet-Reynaud, C., Stura, 
E. A. (2008)  Crystal structure of a ternary complex between human prostate-specific 
antigen, its substrate acyl intermediate and an activating antibody. Journal of Molecular 
Biology; 376(4):1021–33.  
60.  Sumi, S., Arai, K., Yoshida, K. (2001) Separation methods applicable to prostate cancer 
diagnosis and monitoring therapy. Journal of Chromatography B; 764:445–55.  
61.  Armbruster, D. A. (1993) Prostate-specific antigen: Biochemistry, analytical methods, and 
clinical application. Clinical Chemistry; 39(2):181–95.  
62.  Parracino, A., Neves-Petersen, M. T., di Gennaro, A. K., Pettersson, K., Lövgren, T., 
Petersen, S. B. (2010) Arraying prostate specific antigen PSA and Fab anti-PSA using 
light-assisted molecular immobilization technology. Protein Science; 19(9):1751–9.  
63.  Kumar, V., Hassan, M. I., Singh, A. K., Dey, S., Singh, T. P., Yadav, S. (2009) Strategy 
for sensitive and specific detection of molecular forms of PSA based on 2DE and kinetic 
analysis: a step towards diagnosis of prostate cancer. Clinica Chimica Acta 403(1-2):17–22 
64.  Balk, S. P. (2003) Biology of Prostate-Specific Antigen. Journal Clinical Oncology: 383–
91.  
65.  Lilja, H. (2003) Biology of prostate-specific antigen. Urology; 62 (5):27–33.  
66.  Lilja, H., Christensson, A., Dahlén, U., Matikainen, M. T., Nilsson, O., Pettersson, K., 
Lövgren T. (1991) Prostate-specific antigen in serum occurs predominantly in complex 
with α1-antichymotrypsin. Clinical Chemistry; 37(9):1618–25.  
67.  Schlomm, T. (2015) The Era of Prostate-specific Antigen-based Personalized Prostate 
Cancer Screening Has Only Just Begun. European Association of Urology; 68(2):214–5.  
68.  Rao, A. R, Motiwala, H. G., Karim, O. M (2008) The discovery of prostate-specific 
antigen. BJU International; 101(1):5–10.  
69.  Shariat, S. F., Canto, E.I., Kattan, M. W., Slawin, K. M. (2004) Beyond prostate-specific 
antigen: new serologic biomarkers for improved diagnosis and management of prostate 
cancer. Reviews Urology; 6(2):58–72.  
 74 
 
70.  Luboldt, H., Schindler, J.F., Rübben, H. (2007) Age-Specific Reference Ranges for 
Prostate-Specific Antigen as a Marker for Prostate Cancer. European Association of 
Urology. 2007 Feb;5(1):38–48.  
71.  Oesterling, J. E., Jacobsen, S. J., Chute, C. G., Guess, H A., Girman, C. J., Panser, L. A. 
Lieber M. M. (1993) Serum prostate-specific antigen in a community-based population of 
healthy men. Establishment of age-specific reference ranges. JAMA; 270:860–4.  
72.  Linton, K. D., Catto, J. W. F. (2013) Prostate cancer. Renal and urological surgery; 31 
(10):516–22.  
73.  Velonas, V., Woo, H., Remedios, C., Assinder. S. (2013) Current Status of Biomarkers for 
Prostate Cancer. International Journal of Molecular Sciences.;14 (6):11034–60.  
74.  Jaenicke, R., Knof, S., (1968) Molecular Weight and Quaternary Structure of Lactic 
Dehydrogenase. 3. Comparative Determination by Sedimentation Analysis, Light 
Scattering and Osmosis. European Journal of Biochemistry; 4(2):157–63.  
75.  Scartozzi, M., Faloppi, L., Bianconi, M., Giampieri, R., Maccaroni, E., Bittoni, A., Prete, 
M., Loretelli, C., Belvederesi, L., Baroni, G., Cascinu, S. (2012) The role of LDH serum 
levels in predicting global outcome in HCC patients undergoing TACE: Implications for 
clinical management. PLoS One.; 7(3):1–8.  
76.  Adams, M. J., Buehner, M., Chandrasekhar, K., Ford, G. C., Hackert, M. L., Liljas, A. 
Structure-function relationships in lactate dehydrogenase. Proceedings of national 
Academy of Sciences;70 (7):1968–72.  
77.  Markert, C. L. (1963) Lactate Dehydrogenase Isozymes: Dissociation and Recombination 
of Subunits. Science; 140(3573):1329–30.  
78.  Phan, L. M., Yeung, S. J, Lee, M. (2014) Cancer metabolic reprogramming : importance, 
main features, and potentials for precise targeted anti-cancer therapies Cancer metabolism : 
major remodeling of cellular energy production and metabolic. Cancer Biology & 
Medicine; (11):1–19.  
79.  Vander Heiden, M. G., Cantley, L. C., Thompson, C. B (2009) Understanding the Warburg 
Effect: The Metabolic Requirements of Cell Proliferation. Science; 324(5930):1029–33.  
80.  Maxwell, P. H., Dachs, G. U., Gleadle, J. M., Nicholls, L. G., Harris, A. L., Stratford, I. J., 
Stratford I. J., Hankinson O., Pugh C. W., Ratcliffe P. J. Hypoxia-inducible factor-1 
modulates gene expression in solid tumors and influences both angiogenesis and tumor 
growth. Proceedings of national Academy of Sciences; 94(15):8104–9.  
 75 
 
81.  Augoff, K., Hryniewicz-jankowska, A., Tabola, R. (2015) Lactate dehydrogenase 5: An 
old friend and a new hope in the war on cancer. Cancer Letters; 358(1):1–7.  
82         National Cancer Institute at the National Institutes of Health. Tumorous markers (2015) 
Acessed on November 8, 2015. Available from http://www.cancer.gov/about-
cancer/diagnosis-staging/diagnosis/tumor-markers-fact-sheet. 
83.  Ziaian, B., Saberi, A., Ghayyoumi, M. A., Safaei, A., Ghaderi, A., Mojtahedi, Z. (2014) 
Association of high LDH and low glucose levels in pleural space with HER2 expression in 
non-small cell lung cancer. Asian Pacific Journal of Cancer Prevention: 1617–20.  
84.  Chen, J., Sun, M-X., Hua, Y-Q., Cai, Z-D. (2014) Prognostic significance of serum lactate 
dehydrogenase level in osteosarcoma: a meta-analysis. Journal of Cancer Research and 
Clinical Oncology; 0–5.  
85.  Girgis, H., Masui, O., White, N. M., Scorilas, A., Rotondo, F., Seivwright, A, Gabril, M., 
Filter, E. R., Girgis A. H., Bjarnason, G. A., Jewett, M. A., Evans, A., Al-Haddad, S., Siu, 
K. M., Yousef, G. M. (2014) Lactate dehydrogenase A is a potential prognostic marker in 
clear cell renal cell carcinoma. Molecular Cancer; 13(1):101.  
86.  Hermes, A., Gatzemeier, U., Waschki, B., Reck, M. (2010) Lactate dehydrogenase as 
prognostic factor in limited and extensive disease stage small cell lung cancer - A 
retrospective single institution analysis. Respiratory Medicine;104 (12):1937–42. 
87.  Nishikawa, A., Tanaka, T., Takeuchi, T., Fujihiro, S., Mori, H. (1991) The diagnostic 
significance of lactate dehydrogenase isoenzymes in urinary cytology. British Journal of 
Cancer; 63(5):819–21.  
88.  Flocks, R. H., Schmidt, J. D. (1961) Lactate Dehydrogenase Isoenzyme Patterns of 
Prostatic Cancer and Hyperplasia. Journal Surgical Oncoly; 161–7.  
89.  Prout, G. R., Macalalag, E. V., Denis, L. J. Preston, L. W. (1965) Alterations in serum 
lactate dehydrogenase and its fourth and fifth isozymes in patients with prostatic 
carcinoma. Journal of Urology; 94:451–61.  
90.  Naruse, K., Yamada, Y., Aoki, S., Taki, T., Nakamura, K., Tomiume, M., Zennami, K., 
Katsuda, R., Sai, S., Nishio, Y., Inoue, Y., Noguchi, H., Honda, N. (2007) Lactate 
Dehydrogenase is a Prognostic indicator for Prostate Cancer patients with Bone Metastasis. 
Hinyokika Kiyo.; 53(5):287-92. 
91.  Brown, J. E., Cook, R. J., Lipton, A., Colema, R. E. (2012) Serum Lactate Dehydrogenase 
Is Prognostic for Survival in Patients with Bone Metastases from Breast Cancer : A 
 76 
 
Retrospective Analysis in Bisphosphonate-Treated Patients. American Association for 
Cancer Research; (8):1–8.  
92.  Koukourakis, M. I., Giatromanolaki, A., Panteliadou, M., Pouliliou, S. E., Chondrou PS, 
Mavropoulou, S.,  Sivridis, E. (2014) Lactate dehydrogenase 5 isoenzyme overexpression 
defines resistance of prostate cancer to radiotherapy. British Journal of Cancer; 110 
(9):2217–23.  
93.  Scher, H. I., Heller, G., Molina, A., Attard, G., Danila, D. C., Jia, X., Peng, W., Sandhu, S. 
Riisnaes, R., McCormack, R., Burzykowski, T., Kheon, T., Fleisher, M., Buyse, M., Bono 
J. S. (2015) Circulating Tumor Cell Biomarker Panel As an Individual-Level Surrogate for 
Survival in Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology; 
33(12):1348–55.  
94.  Sidaway, P. (2015) Prostate cancer: New biomarker panel prognosticates patient survival. 
Nature Reviews Clinical Oncology; 12(6):310–310.  
95.  Petrelli, F., Cabiddu, M., Coinu, A., Borgonovo, K., Ghilardi, M., Lonati, V., Sandro, B. 
(2015) Prognostic role of lactate dehydrogenase in solid tumors: A systematic review and 
meta-analysis of 76 studies. Acta of Oncology; 54(7):961–70 
96.  Bylda, C., Thiele, R., Kobold, U., Volmer, D. A. (2014) Recent advances in sample 
preparation techniques to overcome difficulties encountered during quantitative analysis of 
small molecules from biofluids using LC-MS/MS. Analyst;139(10):2265.  
97.  Lopez, M. F. (2005) High-Resolution Serum Proteomic Profiling of Alzheimer Disease 
Samples Reveals Disease-Specific, Carrier-Protein-Bound Mass Signatures. Clinical 
Chemistry; 51(10):1946–54.  
98.  Bock, J. (1949) Serum Protein Concentration and Relative Albumin Percentage in Normal 
Individuals. Acta physiological; 18:231-237;  
99.  Ayache, S., Panelli, M., Marincola, F. M., Stroncek, D. F. (2006) Effects of storage time 
and exogenous protease inhibitors on plasma protein levels. American Journal of Clinical 
Pathology;126:174–84.  
100.  Bylda, C., Thiele, R., Kobold, U., Volmer, D. A. (2013) Simultaneous quantification of 
acetaminophen and structurally related compounds in human serum and plasma. Drug Test 
and Analysis  
101.  Wu, X., Xiong, E., Wang, W., Scali, M., Cresti, M. (2014) Universal sample preparation 
method integrating trichloroacetic acid/acetone precipitation with phenol extraction for 
crop proteomic analysis. Nature Protocols; 9(2):362–74.  
 77 
 
102.  Truong, M., Yang, B., Jarrard, D. F. (2013) Toward the detection of prostate cancer in 
urine: a critical analysis. Journal of Urology; 189(2):422–9.  
103.  Yaroshenko, I., Kirsanov, D., Kartsova, L., Sidorova, A., Borisova, I., Legin, A. (2015) 
Determination of urine ionic composition with potentiometric multisensor system. Talanta; 
131:556–61.  
104.  Taylor, T. P., Janech, M. G.,  Slate, E. H., Lewis, E. C., Arthur, J. M., Oates, J. C. (2012) 
Overcoming the Effects of Matrix Interference in the Measurement of Urine Protein 
Analytes. Biomark Insights; 7: 1-8.  
105.  Struck-Lewicka, W., Kordalewska, M., Bujak, R., Mpanga, A. Y., Markuszewski, M.  
Jacyna, J., Matuszewski, M., Kaliszan, R., Markuszewski, M. J. (2015) Urine metabolic 
fingerprinting using LC–MS and GC–MS reveals metabolite changes in prostate cancer: A 
pilot study. Journal of Pharmaceutical and Biomedical Analysis; 111:351–61.  
106.  Jacobs, E., Hissin, P. J., Propper, W., Mayer, L., Sarkozi, L. (1986) Stability of lactate 
dehydrogenase at different storage temperatures. Clinical Biochemistry; 19(3):183–8.  
107.  Kreutzer, H. H., Fennis, W. H. S. (1964) Lactic dehydrogenase after storage in blood 
serum tempertaures. Clinical Chimica Acta; 9:64–8.  
108.  Shain, S. A., Boesel, R. W., Klipper, R. W., Lancaster, C. M. (1983) Creatine kinase and 
lactate dehydrogenase: stability of isoenzymes and their activity in stored human plasma 
and prostatic tissue extracts and effect of sample dilution. Clinical Chemistry; 29(5):832–5.  
109.  Arcangeli, C. G., Smith, D. S., Ratliff, T. L., Catalona, W. J. (1997) Stability of serum total 
and free prostate specific antigen under veryng storage intervals and temperatures. Journal 
of Urology; 158:2182–7.  
110.  Arneth, B. M. (2009) Clinical Significance of Measuring Prostate-Specific Antigen. Lab 
Med; 40(8):487–91.  
111.  Kuriyama, M., Wang, M. C., Papsidero, L. D., Killian, C.S., Shimano, T., Valenzuela, L., 
Nishiura, T., Murphy, G.p., Chu, T. M. (1980) Quantitation of Prostate-specific Antigen in 
Serum by a Sensitive Enzyme Immunoassay. Cancer Research; 40:4568–662.  
112.  Acevedo, B., Perera, Y., Ruiz, M., Rojas, G., Benítez, J., Ayala, M., Gavilondo, J. (2002) 
Development and validation of a quantitative ELISA for the measurement of PSA 
concentration. Clinical Chimica Acta; 317(1-2):55–63.  
113.  Ahmed H. A., Azzazy. H. M. (2013) Power-free chip enzyme immunoassay for detection 
of prostate specific antigen (PSA) in serum. Biosensors and Bioelectronics; 49:478–84.  
 78 
 
114  Scheijen, J. L. J. M., Hanssen, N. M .J., van de Waarenburg, M. P. H., Jonkers, D. M A. E., 
Stehouwer, C. D. A., Schalkwijk, C. G. (2012) L (+) and D(-) lactate are increased in 
plasma and urine samples of type 2 diabetes as measured by a simultaneous quantification 
of L(+) and D(-) lactate by reversed-phase liquid chromatography tandem mass 
spectrometry. Experimental Diabetes Research: 234812.  
115.  Cheow, L.F.  Ko, S. H. Kim, S. J.  Kang, K. H.  Han., J. (2011) Increasing the Sensitivity 
of ELISA using Multiplexed Electrokinetic Concentrator. Analytical Chemistry.; 
82(8):3383–8. 
116.  Poon, C-Y., Chan, H-M., Li, H-W. (2014) Direct detection of prostate specific antigen by 
darkfield microscopy using single immunotargeting silver nanoparticle. Sensors Actuators 
B Chemical: 737–44.  
117.  Stenman, U. H., Leinonen, J., Alfthan, H., Rannikko, S., Tuhkanen, K., Alfthan, O. (1991) 
A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major 
form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the 
complex improves clinical sensitivity for cancer. Cancer Research; 51(1):222–6.  
118.  Simon, R., Passeron, S., Lemoine, J., Salvador, A. (2014) Hydrophilic interaction liquid 
chromatography as second dimension in multidimensional chromatography with an anionic 
trapping strategy: application to prostate-specific antigen quantification. Journal of 
Chromatography; 1354:75–84.  
119.  Cao, C., Kim, J.P., Kim, B. W, Chae, H., Yoon, H. C., Yang, S. S. Sim, S. J. (2006)  A 
strategy for sensitivity and specificity enhancements in prostate specific antigen-α1-
antichymotrypsin detection based on surface plasmon resonance. Biosensors 
Bioelectronics: 2106–13.  
120.  Nandakumar, M. P., Nandakumar, R., Mattiasson, B. (2000) Fluorimetric quantification of 
intracellular lactate dehydrogenase during fermentation using flow injection analysis. 
Biotechnology Letters; 22(18):1453–7.  
121.  Pettit, S. M., Nealon, D. A.., Henderson, A. R. (1981) Purification of lactate 
dehydrogenase isoenzyme-5 from human liver. Clinical Chemistry; 27(1):88–93.  
122.  Nesakumar, N., Thandavan, K., Sethuraman, S., Krishnan, U. M., Rayappan, J. B. B. 
(2014) An electrochemical biosensor with nanointerface for lactate detection based on 
lactate dehydrogenase immobilized on zinc oxide nanorods. Journal of Colloid Interface 
Science; 414:90–6 
 79 
 
123.  Sahab, Z. J., Semaan, S. M., Sang, Q. A. (2007) Methodology and applications of disease 
biomarker identification in human serum. Biomarker Insights; 2:21–43.  
124.  Sapan, C. V., Lundblad, R. L., Price, N. C. (1999) Colorimetric protein assay techniques. 
Biotechnology and applied Biochemistry; 29:99–108.  
125.  McMaster, M. C. (2006) HPLC: A pratical user’s guide. Analytical Chemistry;Second 
Ed.:3–13.  
126.  Bai, Y. J., Gao, X. Y., Lu, J. Q., Zhang, H. G. (2010) A LC-MS-based method for 
quantification of biomarkers from serum of allergic rats. Molecules; 15:3356–65 
127.  Freire, M. G., Pereira, J. F. B., Francisco, M., Rodríguez, H., Rebelo, L. P., Rogers, R. D., 
Coutinho, J. A. (2012) Insight into the interactions that control the phase behaviour of new 
aqueous biphasic systems composed of polyethylene glycol polymers and ionic liquids. 
Chemistry; 18(6):1831–9.  
128.  Albertson, P-A. (1958) Particle fractionation in liquis two-phase systems;The composition 
of some phase systems and the behaviour of some model particles in them aplication to the 
isolation of cell walls from microorganisms. Biochimica et Biophysica Acta; 27(958):378–
95.  
129.  Willauer, H. D. , Huddleston, J. G., Rogers, R. D. (2002) Solute Partitioning in Aqueous 
Biphasic Systems Composed of Polyethylene Glycol and Salt:  The Partitioning of Small 
Neutral Organic Species. Ind Eng Chem Res. American Chemical Society: 1892–904.  
130.  Freire, M. G., Cláudio, A. F. M., Araújo, J. M. M., Coutinho, J. A. Marrucho, I. M., Lopes, 
J. N. C., Rebelo, L. P. (2012) Aqueous biphasic systems: a boost brought about by using 
ionic liquids. Chemistry Society Reviews; 41(14):4966–95.  
131.  Raja, S., Murty, V. R., Thivaharan, V., Rajasekar, V., Ramesh, V (2012). Aqueous Two 
Phase Systems for the Recovery of Biomolecules – A Review. Science Technology: 
1(1):7–16.  
132.  Pei, Y., Wang, J., Wu, K., Xuan, X., Lu, X. (2009) Ionic liquid-based aqueous two-phase 
extraction of selected proteins. Separation and Purification Technology; 64(3):288–95.  
133.  Bai, Z., Chao, Y., Zhang, M., Han, C., Zhu, W., Chang, Y., Li, H. Sun, Y. (2013) 
Partitioning Behavior of Papain in Ionic Liquids-Based Aqueous Two-Phase Systems. 
Journal of Chemistry; 2013:1–6.  
134.  Du, Z., Yu, Y-L., Wang, J-H. (2007) Extraction of proteins from biological fluids by use of 
an ionic liquid/aqueous two-phase system. Chemistry; 13(7):2130–7.  
 80 
 
135.  Passos, H., Sousa, A. C. A., Pastorinho, M. R., Nogueira, J. A., Rebelo, P. N., Coutinho, J. 
A. P., Freire M. G. (2012) Analytical Methods Ionic-liquid-based aqueous biphasic 
systems for improved detection of bisphenol A in human fluids †‡. Analytical methods; 
4:2664–7.  
136.  Pereira, M. M., Pedro, S. N., Quental, M. V., Lima, A. S., Coutinho, J. A. P., Freire, M. G. 
(2015) Enhanced extraction of bovine serum albumin with aqueous biphasic systems of 
phosphonium- and ammonium-based ionic liquids. Journal of Biotechnology; 206:17–25.  
137.  Walden, P., (1914) Molecular weights and electrical conductivity of several fused salts. 
Bulletin of the Russian Academy of Sciences; 405–22.  
138.  Gutowski, K.E., Broker, G. A., Willauer, H. D., Huddleston J. G., Swatloski, R. P., 
Holbrey, J. D., Rogers, R. D. (2003) Controlling the aqueous miscibility of ionic liquids: 
aqueous biphasic systems of water-miscible ionic liquids and water-structuring salts for 
recycle, metathesis, and separations. Journal of the American Chemistry Society; 
125(22):6632–3.  
139.   Earle, M. J., Esperança,  J. M. S. S., Gile, M. A., Lopes, J. N. C., Rebelo, L. P. N., Magee, 
J. W., Seddon, K. R., Windegren, J. A. (2005) The distillation and volatility of ionic 
liquids. Nature; 439:831–4.  
140.   Parshall, W. G. (1977) Inorganic Syntheses; 17, 110.  
141.   Manzer, L. E., Parshall, G. W., (1976) Lewis acid adducts of trans-
hydrocyanobis(triethylphosphine)platinum. Inorganic Chemistry; 15(12):3114–6.  
142. Fraser, K. J., MacFarlane, D. R. (2009) Phosphonium-Based Ionic Liquids: An Overview. 
Australian Jouranl of Chemistry; 62(4):309.  
143. Ermolaev, V., Miluykov, V., Rizvanov, I., Krivolapov, D., Zvereva, E., Katsyuba, S., 
Sinyashin, O., Schmutzler, R. (2010) Phosphonium ionic liquids based on bulky 
phosphines: synthesis, structure and properties. Dalton Transactions; 39(23):5564–71.  
144. Louros, C. L. S., Cláudio, A. F. M., Neves, C. M. S. S., Freire, M. G., Marrucho, I. M., 
Pauly, J., Coutinho, J. A. P. (2010) Extraction of biomolecules using phosphonium-based 
ionic liquids + K(3)PO(4) aqueous biphasic systems. International Journal of Molecular 
Sciences; 11(4):1777–91. 
 81 
 
145. Kozlowska, K., Polkowska, Z., Przyjazny, A., Namiesnik, J. (2003) Analytical procedures 
used in examining human urine samples. Polish Journal of Environmental Studies; 
12(5):503–21.  
146. Diamandis, E. P. (1998) Prostate specific antigen- its usefulness in clinical medicine. 
Trends in Endocrinology & Metabolism; 9:310–6.  
147.  Sia, M., Pickles, T. Morton, G., Souhami, L., Lukka, H., Warde, P. (2008) Salvage 
radiotherapy following biochemical relap after radical prostatectomy proceedings of the 
Genito-Urinary Radiation Oncologists of Canada consensus meeting. Cancer Urological 
Association Journal; 2:500–7.  
148.  Wilson, D. H., Hanlon, D. W., Provuncher, G. K., Chang, L., Song, L., Patel, P.P., Ferrell, 
E.P., Lepor, H., Partin, A.W., Chan, D. W. Sokoll, L. J., Cheli, C. D., Thiel R. P, . 
Fournier, D. R., Duffy, D. C. (2011) Fifth-Generation Digital Immunoassay for Prostate-
Specific Antigen Using Single Molecule Arrays. Clinical Chemistry; 57:1712–21. 
149.  Zhang, Q. Y., Chen, H., Lin, Z., Lin, J. M. (2012) Comparison of chemiluminescence 
enzyme immunoassay based on magnetic microparticles with traditional colorimetric 
ELISA for the detection of serum alpha-fetoprotein. Journal of Pharmaceutical Analysis; 
2(2):130–5.  
150.  Tate, J., Ward, G. (2004) Interferences in immunoassay; 25:105–20.  
151.  Shipkova, M., Vogeser, M., Ramos, P. A., Verstraete, A. G., Orth, M., Schneider, C., 
Wallemacq, P. (2014) Multi-center analytical evaluation of a novel automated tacrolimus 
immunoassay. Clinical Biochemistry; 47(12):1069–77.  
152.  Dinis, T. B. V., Passos, H., Lima, D. L. D., Esteves, V. I., Coutinho, J. A. P., Freire, M. G. 
(2015) One-step extraction and concentration of estrogens for an adequate monitoring of 
wastewater using ionic-liquid-based aqueous biphasic systems. Green 
Chemistry.;17(4):2570–9.  
153.  Passos, H., Ferreira, A. R., Cláudio, A. F. M., Coutinho, J. A. P., Freire, M. G. (2012) 
Characterization of aqueous biphasic systems composed of ionic liquids and a citrate-based 
biodegradable salt. Biochemical Engineering Journal; 67:68–76.  
 82 
 
154.  Merchuk, J. C., Andrews, B. A., Asenjo, J. A. (1998) Aqueous two-phase systems for 
protein separation. Studies on phase inversion. Journal of Chromatography B: Biomedical 
Sciences and Applications; 711(1-2):285–93.  
155.  Sintra, T. E., Cruz, R., Ventura, S. P. M., Coutinho, J. A. P. (2014) Phase diagrams of ionic 
liquids-based aqueous biphasic systems as a platform for extraction processes. Journal of 
Chemical Thermodynamics; 77:206-213.  
156.  Zhang, Y., Cremer, P. S. (2006) Interactions between macromolecules and ions: the 
Hofmeister series. Current Opinion in Chemical Biology; 10(6):658–63.  
157.  Kumar, A., Venkatesu, P. (2014) Does the stability of proteins in ionic liquids obey the 
Hofmeister series? International Journal of Biological Macromolecules; 63:244–53.  
158.  Bouatra, S., Aziat, F., Mandal, R., Guo, A. C., Wilson, M. R., Knox, C., Bjorndahl, T. C., 
Ramanarayan, K., Saleem, F., Serihun, P. L., Liu, P., Dame, Z. T., Poelzer, J., Huynh, j., 
Yallou, F. S., Psychogios, N., Dong, E., Bogumil, R., Roehring, C., Wishart, D. S. (2013) 
The Human Urine Metabolome. PloS One; 8(9).  
159.  Steel, L. F., Trotter, M. G., Nakajima, P. B., Mattu, T. S., Gonye, G., Block, T. (2013) 
Efficient and specific removal of albumin from human serum samples. Molecular & 
Cellular Proteomics; 2(4):262–70.  
160.  Merrell, K, Southwick, K., Graves, S. W., Esplin, M. S., Lewis, N. E., Thulin, C. D. (2004) 
Analysis of low-abundance, low-molecular-weight serum proteins using mass 
spectrometry. Journal of Biomolecular Techniques.; 15(4):238–48.  
161.  Bertholf, R. L. (2014) Proteins and Albumin. (2014) Laboratory Medicine.; 45(1):25–45.  
162.  Chang, M., (2011) Automated Sample Preparation by Protein Precipitation for High 
Throughput Bioanalysis. Agilent Technologies.  
163.  Roe S. (2001) Protein Purification Techniques. 2nd Ed. Oxford Univ Press; 4(8):238.  
164.  Coligan, J. E., Dunn, B. M., Ploegh, H. L., Speicher, D. W., Wingfield P. T. (1996) 
Current protocols in protein science. Proteins Structure, Function and Genetics; 24(3):409–
409.  
165.  Burgess, R. R. (2009) Protein Precipitation Techniques. Chapter 20 1st Ed. Methods in 
Enzymology. 331-342. 
 83 
 
166.  Anderson, N. L. (2002) The human plasma proteome: history, character, and diagnostic 
prospects. Molecular & Cellular Proteomics; 1(11):845–67.  
167.  Paulus, A., Freeby, S., Academia, K., Thulasiraman, V., Wehr, T., Liu, N., Roth, S., Smith, 
K. (2009) Accessing Low-Abundance Proteins in Serum and Plasma With a Novel, Simple 
Enrichment and Depletion Method; Bio-Rad 6.  
168.  Venderlinde, R. E. (1985) Measurement of Total Lactate Dehydrogenase Activity. 
Academy of Clinical and Labotarory Science; 15.  
169.  Buonocore, R., Avanzini, P., Aloe, R., Lippi, G. (2015).Analytical imprecision of lactate 
dehydrogenase in primary serum tubes. Annals of Clinical Biochemistry; 0(0):1–4.  
170.  Burd, J. F., Usategui-Gomez, M. (1973) A colorimetric assay for serum lactate 
dehydrogenase. Clinical Chemistry Acta.; 46(3):223–7.  
171.  Wiener Lab. (2013) Optimized UV method (SFBC) for the determination of lactate 
dehydrogenase (LDH) in serum or plasma. Journal of Chemical Information and 
Modeling.; 53(9):1689–99.  
172.  Bisswanger, H. (2014) Enzyme assays. Perspectives in Science; 1(1-6):41–55.  
173.  Cláudio, A. F. M., Marques, C. F.C., Boal-Palheiros, I., Freire, M. G., Coutinho. J. A. P. 
(2014) Development of back-extraction and recyclability routes for ionic-liquid-based 
aqueous two-phase systems. Green Chemistry; 16(1):259. 
174.  Arakawa, T., Kita, Y., Timasheff, S. N. (2007) Protein precipitation and denaturation by 
dimethyl sulfoxide. Biophysical Chemistry; 131(1-3):62–70.  
175.  Kumar, V., Sharma, V. K., Kalonia, D. S. (2009) Effect of polyols on polyethylene glycol 
(PEG)-induced precipitation of proteins: Impact on solubility, stability and conformation. 
International Journal of Pharmaceutics; 366(1-2):38–43.  
176.  Zhang, Y., Furyk, S., Sagle, L. B., Cho, Y., Bergbreiter, D. E., Cremer, P. S. ( 2008) 
Effects of Hofmeister Anions on the LCST of PNIPAM as a Function of Molecular 
Weight. Journal of Physics; 111(25):8916–24.  
177. Dreyer, S. E. (2008) Aqueous two-phase extraction of proteins and enzymes using 
tetraalkylammonium-based ionic liquids. Rostock.  
 84 
 
178.  Nascimento, K. S., Rosa, P. A. J., Nascimento, K. S., Cavada, B. S., Azevedo. A. M., 
Aires-Barros, M. R. (2010) Partitioning and recovery of Canavalia brasiliensis lectin by 
aqueous two-phase systems using design of experiments methodology. Separation and 
Purification Technology; 75(1):48–54. 
179.  Date, M. S., Dominy, B. N. (2013) Modeling the Influence of Salt on the Hydrophobic 
Effect and Protein Fold Stability. Communications in Computational Physics; 13(1):90–
106.  
180.  Pieper, R., Gatlin, C. L., Makusky, A. J., Russo, P. S., Schatz, C. R., Miller, S. S., Su, Q., 
McGrath, A. M., Estock, M. A., Parmar, P. P., Zhao, M., Huang, S. T., Zhou, J., Wang, F., 
Esquer-Blasco, R., Anderson, N. L., Taylor, J., Steiner, S., (2003) The human serum 
proteome: Display of nearly 3700 chromatographically separated protein spots on two-
dimensional electrophoresis gels and identification of 325 distinct proteins. Proteomics; 
3(7):1345–64.  
181.  Schneider, S., Pechtl, I. (2016) Affinity Removal of the 14 Most Abundant Proteins in 
Human Plasma Using the Agilent 1260 Infinity Bio-inert Quaternary LC System. 
Proteomics & Protein Sciences. Agilent Tecn.  
   
 
 
 
 
 
 
 85 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix A 
Experimental binodal data 
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A.1. Experimental Binodal Data for the system composed by IL+ salt+ H2O. 
 
Table A.1.1. Experimental weight fraction data for the binodal curve of the system 
composed of [P4444]Cl (1) + C6H5K3O7 (2) at (25±1)
 ºC (153). 
 
 [P4444]Cl 
100 w1 100 w2 
58.615 5.560 
48.752 6.944 
44.978 7.422 
41.69 8.008 
39.23 8.576 
37.264 9.152 
35.572 9.565 
34.403 10.185 
32.774 10.653 
30.815 11.472 
29.945 11.865 
29.106 12.239 
28.391 12.628 
27.604 13.153 
26.488 14.022 
25.787 14.359 
24.266 15.595 
23.756 15.842 
23.301 16.071 
22.823 16.325 
22.317 16.602 
21.646 17.189 
21.036 17.666 
20.328 18.224 
19.959 18.434 
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19.044 19.115 
18.453 19.702 
17.747 20.163 
17.163 20.506 
16.763 20.881 
16.383 21.245 
16.018 21.566 
15.632 21.918 
15.301 22.229 
15.083 22.318 
14.701 22.663 
14.377 23.025 
14.133 23.141 
13.756 23.523 
13.55 23.612 
13.266 23.904 
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Table A.1.2. Experimental weight fraction data for the binodal curve of the systems 
composed of IL (1) + C6H5K3O7/C6H8O7 (2) at (25±1)
 ◦C (136). 
 
[P4444]Br [P4444]Cl 
100 w1 100 w2 100 w1 100 w2 
47.839 0.437 56.699 1.319 
43.160 0.659 47.438 2.980 
40.112 0.898 41.147 4.204 
38.124 1.066 38.327 5.482 
36.379 1.189 35.791 6.057 
33.514 1.641 31.067 7.538 
30.257 2.153 29.428 8.173 
19.226 5.164 28.183 9.020 
9.502 15.005 26.944 9.657 
5.789 23.234 25.574 9.946 
5.251 26.355 23.989 11.278 
4.639 26.556 23.048 11.725 
3.943 28.360 22.412 12.032 
3.209 29.345 21.228 12.931 
3.088 31.056 20.521 13.370 
2.053 40.229 19.996 13.912 
1.629 42.954 19.329 14.166 
1.431 43.091 18.534 14.899 
1.191 43.959 18.024 15.111 
  
17.212 15.937 
16.718 16.236 
16.092 16.718 
15.644 17.001 
15.208 17.350 
14.663 17.862 
14.484 17.635 
13.788 18.604 
13.221 18.808 
12.766 19.299 
12.286 19.792 
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12.257 19.183 
11.473 19.096 
10.896 19.616 
10.488 19.697 
9.979 20.579 
9.709 20.918 
9.220 21.536 
8.809 21.902 
8.451 22.391 
8.001 23.208 
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         A.2. Phase diagrams for the systems composed of IL+ salt+ H2O. 
0
10
20
30
40
50
60
70
80
90
100
0 20 40 60 80
[P
4
4
4
4
]C
l /
(w
t%
)
[C6H5K3O7] /(wt%)
 
Figure A.2.1- Phase diagram for the system composed by [P4444]Cl(♦) 
+C6H5K3O7/C6H8O7 + H2O at 25◦C and pH= 7.0 (153).  
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Figure A.2.2- Phase diagrams for the systems composed by C6H5K3O7/C6H8O7 + H2O + 
IL at 25◦C and pH= 7.0: [P4444]Br (●); + [P4444]Cl (■)  (136).  
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A.3. Correlation parameters for the systems composed of IL+ salt+ H2O. 
 
Table A.3.1- Correlation parameters obtained by the regression of the experimental data 
through the application of equation (1) and respective standard deviations (σ) and 
correlation coefficient (R2) (153).  
IL A ± σ B ± σ 105 (C ± σ) R2 
[P4444]Cl 170.0 ± 5.7 -0.484 ± 0.011 1.64 ± 0.14 0.994 
 
 
Table A.3.2- Correlation parameters obtained by the regression of the experimental data 
thought the application of Eq. (1) and respective deviations (σ) and correlation coefficient 
(R2) (136).  
IL A ± σ B ± σ 105 (C ± σ) R2 
[P4444]Cl 116.40 ± 2.65 −0.399 ± 0.009 3.05 ± 0.20 0.985 
[P4444]Br 66.13 ± 0.98 −0.527 ± 0.013 0.21 ± 0.24 0.998 
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Experimental data for CF 
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 95 
 
     B.1. Experimental data for the concentration factors in ABS composed of 
IL + salt + H2O. 
 
    Table B1.1. CF of the system composed of [P4444]Cl + C6H5K3O7 + H2O at (25±1)
 ◦C.  
[P4444]Cl 
Theoretical 
CF 
5 20 50 100 150 200 250 
w IL/ g 0.1415 0.2038 0.8574 0.4589 0.3246 0.2572 0.2218 
w Salt/ g 0.5191 2.882 25.64 29.92 30.02 30.07 30.34 
w H2O/g 0.3570 1.919 19.51 19.63 19.66 19.67 19.83 
w top/ g 0.0732 0.0834 0.3495 0.2032 0.1258 0.1007 0.0792 
w bottom/ g 0.9188 4.694 44.83 48.85 49.13 50.29 49.93 
Real CF 4.880 23.01 55.82 96.60 156.3 195.3 250.4 
 
 
. 
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SE-HPLC calibration curves 
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C.1 SE-HPLC calibration curve for LDH. 
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Figure C.1. Calibration curve for LDH in PBS aqueous solution by SE-HPLC at 280 nm. 
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SE-HPLC profiles 
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D.1 SE-HPLC chromatograms for extractions of LDH from synthetic samples 
and serum. 
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B
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Figure D1.1- HPLC chromatogram of the top (˗) and bottom phases (- -) of the ABS 
composed of [P4444]Br (A) or [P4444]Cl (B) + C6H5K3O7/C6H8O7 , at 25ºC and pH 7.0, 
corresponding to the extraction of LDH. 
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Figure D1.2- HPLC chromatogram of the top (˗) and bottom phases (- -) of the ABS 
composed of [P4444]Br (A) or [P4444]Cl (B) + C6H5K3O7/C6H8O7 , at 25ºC and pH 7.0, 
corresponding to the extraction of serum. 
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